Synthesis of 2'-acetyl ester-protected nucleosides

Novel 2'-protected nucleoside phosphoramidites with improved protecting groups address the challenges of harsh conditions and migration in RNA synthesis, enhancing efficiency and yield by allowing easy and safe removal.

JP2024544494AInactive Publication Date: 2024-12-03ホンジーン バイオテック コーポレイション
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2024526585
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-11-29
Filing Date
2022-11-28
Publication Date
2024-12-03
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Existing nucleoside phosphoramidites for RNA synthesis face challenges such as the need for harsh or toxic conditions for protecting group removal, low yields, and undesired migration of protecting groups from the 2' to the 3' position, which affect the efficiency and stability of oligonucleotide synthesis.

Method used

Development of novel 2'-protected nucleoside phosphoramidites with improved protecting groups, such as (4-methoxyphenyl)diphenylmethyl and trityl types, that allow for easy removal under mild conditions and reduce migration, enhancing synthesis efficiency and yield.

Benefits of technology

The novel protecting groups facilitate efficient and stable RNA synthesis by enabling easy removal without toxic reagents and minimizing undesired migration, thereby improving overall yield and process efficiency.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024544494000001_ABST
    Figure 2024544494000001_ABST
Patent Text Reader

Abstract

The embodiments of the present application relate to the preparation of 2'-O-protected nucleoside phosphoramidites and the conjugation of 2'-O-protected nucleosides to solid supports. More specifically, the present application relates to nucleosides with hydroxyl protecting groups at the 2' position, which reduce migration to the 3' position during RNA (e.g., mRNA) synthesis and can be easily removed under mild conditions without using toxic metal-containing reagents. Methods of using the nucleosides described herein in RNA synthesis are also disclosed.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] Field This application relates to 2'-protected nucleosides, methods for their preparation and their use in oligonucleotide synthesis. More particularly, this application relates to nucleoside phosphoramidites for use in RNA synthesis.

[0002] Reference to sequence listing This application has been filed with a Sequence Listing in electronic format, which is provided as a file entitled "HGENE.010WO_Sequence_Listing.xml", created on November 28, 2022, and having a size of 1.90 KB. The information in the electronic format of this Sequence Listing is incorporated herein by reference in its entirety. [Background technology]

[0003] background 2. Description of Related Art Oligonucleotide-based drugs have become a powerful model with the ability to treat various diseases. Due to the commercial availability of automated synthesis equipment, solid-phase synthesis can be used to rapidly prepare a given oligonucleotide sequence in large quantities. Preparation of stable nucleoside synthons, such as phosphoramidites, has become a key factor in improving the efficiency of oligonucleotide synthesis. Summary of the Invention [Problem to be solved by the invention]

[0004] Some nucleoside phosphoramidites have been prepared and used in the process of RNA synthesis.The preparation of these phosphoramidites often requires the use of a protecting group at the 2' position of nucleoside phosphoramidite.Examples of the 2' protecting group of nucleoside phosphoramidite include TBDMS (tert-butyldimethylsilyl) group, TOM (triisopropylsilyloxymethyl) group, ACE (bis(2-acetoxyethoxy)methyl) group, TC (thiomorpholine-4-carbothioate), EMM (cyanoethoxymethoxymethyl), and the like, for example, those disclosed in WO9618736, WO99 / 09044, US6590093, US9273086, WO2008 / 090829, WO2013 / 027843 and WO2016 / 159374. Certain protecting groups may require several steps of synthesis and low final yields. Others may be difficult to remove using mild conditions and / or may result in reduced efficiency or yield of oligonucleotide synthesis. Furthermore, a particular challenge faced during the synthesis of these phosphoramidite reagents is the transfer of the protecting group from the 2' to the 3' position of the nucleoside sugar moiety. Furthermore, removal of the protecting group may require harsh or toxic conditions. For example, International Patent Publication No. WO2014 / 148298 describes the transfer of a protecting group to the 2'-O atom of the ribose moiety, which is a -CH 2 OCH 2 The use of a phenyl protecting group has been previously reported. However, removal of this protecting group required the use of tin(IV) chloride, a highly toxic reagent. Thus, there is a need for the design and synthesis of novel 2'-protected nucleoside phosphoramidites that avoid the need to use toxic and harsh deprotection conditions, but with improved stability, reduce / stop 2' to 3' migration, and ultimately also improve product yield. [Means for solving the problem]

[0005] overview Some embodiments of the present disclosure include a compound of formula (I): [ka] or a pharma- ceutically acceptable salt thereof, R 1 is hydrogen or a hydroxy protecting group, R 2 is hydrogen, a hydroxy protecting group, -C(=O)CH 2 CH 2 C(=O)R 3 OR-P(OR 4 )NR 5 R 6 and Alternatively, R 1 and R 2 are joined together to form a 6- to 10-membered heterocyclic ring, R Het is an optionally substituted 5-10 membered heteroaryl or an optionally substituted 5-10 membered heterocyclyl; R 3 is hydroxy, -OR 7 or -NR 8 R 9 and R 4 , R 5 and R 6 are each independently H, unsubstituted C 1 ~C 6 Alkyl or substituted C 1 ~C 6 is alkyl, R 7 is unsubstituted C 1 ~C 6 Alkyl, substituted C 1 ~C 6 is an alkyl or hydroxy protecting group, R 8 and R 9 each independently represents H, unsubstituted or substituted C 1~6 an alkyl or amino protecting group, B is a natural nucleobase, a modified natural nucleobase or a non-natural nucleobase.

[0006] In some embodiments of the compounds of Formula (I), R 1is a trityl-type hydroxy protecting group selected from (4-methoxyphenyl)diphenylmethyl, bis(4-methoxyphenyl)phenylmethyl, tris(4-methoxyphenyl)methyl, 9-phenylxanthen-9-yl, and 9-(4-methoxyphenyl)xanthen-9-yl. 1 is bis(4-methoxyphenyl)phenylmethyl. In another embodiment, R 1 is hydrogen.

[0007] In some embodiments of the compounds of Formula (I), R 2 is hydrogen. In other embodiments, R 2 is a hydroxy protecting group.

[0008] In some embodiments of the compounds of Formula (I), R 2 is -C(=O)CH 2 CH 2 C(=O)R 3 and R 3 is hydroxy, -OR 7 or -NR 8 R 9 In some embodiments, R 7 is unsubstituted C 1 ~C 6 Alkyl, substituted C 1 ~C 6 is an alkyl or hydroxy protecting group. In some embodiments, R 7 is unsubstituted C 1 ~C 6 Alkyl, substituted C 1 ~C 6 is an alkyl or hydroxy protecting group. 2 is -C(=O)CH 2 CH 2 C(=O)OH. In another embodiment, R 2 is -C(=O)CH 2 CH 2 C(=O)NH 2 It is.

[0009] In another embodiment of the compound of formula (I), R 2 -P(OR4 )NR 5 R 6 and R 4 , R 5 and R 6 are each independently H, unsubstituted C 1 ~C 6 Alkyl or substituted C 1 ~C 6 In some embodiments, R 2 -P(OR 4 )NR 5 R 6 and R 4 is a substitution C 1 ~C 6 is alkyl, R 5 and R 6 are each independently an unsubstituted C 1 ~C 6 In some embodiments, R 2 teeth, [ka] It is.

[0010] In some embodiments of the compounds of Formula (I), R 1 and R 2 are joined together to form a 6-10 membered heterocyclic ring. 1 and R 2 are linked together to form a 7-membered heterocyclic ring containing an oxygen atom and a silicon atom. In some embodiments, the compound of formula (I) also has the formula (Ia): [ka] or a pharma- ceutically acceptable salt thereof; A , R B , R C and R D are each independently H, unsubstituted C 1 ~C 6 Alkyl or substituted C 1 ~C 6 In certain embodiments, R A , RB , R C and R D are each isopropyl.

[0011] In some embodiments of the compounds of Formula (I), R Het is an optionally substituted 5-10 membered heteroaryl containing 1-4 heteroatoms selected from the group consisting of O, N, and S. In certain embodiments, R Het is selected from the group consisting of pyridinyl, pyrimidinyl, furanyl, pyrrolyl, thienyl, thiazolyl, isothiazolyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, benzofuranyl, benzimidazolyl, benzopyrazolyl, benzothiazolyl, benzoxazolyl, indolyl and quinolinyl, each optionally substituted by one, two or three substituents Q, each of which is halo, cyano, hydroxy, amino, C 1 ~C 6 Alkyl, C 1 ~C 6 Haloalkyl, Hydroxy (C 1 ~C 6 Alkyl), Amino (C 1 ~C 6 Alkyl), (C 1 ~C 6 Alkyl)amino, C 1 ~C 6 Alkoxy, C 1 ~C 6 Haloalkoxy, (C 1 ~C 6 Alkoxy)C 1 ~C 6 Alkyl and -O(C 1 ~C 6 Alkoxy)C 1 ~C 6 In some embodiments, R Het is 4-pyridinyl optionally substituted with one, two or three substituents Q. In another embodiment of the compound of formula (I), R Hetis an optionally substituted 5-10 membered heterocyclyl containing 1-4 heteroatoms selected from the group consisting of O, N, and S. In certain embodiments, R Het is selected from the group consisting of tetrahydrofuranyl, tetrahydropyranyl, pyrrolidinyl, piperidinyl, piperazinyl and morpholinyl, each optionally substituted with one, two or three substituents Q, each of which is halo, cyano, hydroxy, amino, C 1 ~C 6 Alkyl, C 1 ~C 6 Haloalkyl, Hydroxy (C 1 ~C 6 Alkyl), Amino (C 1 ~C 6 Alkyl), (C 1 ~C 6 Alkyl)amino, C 1 ~C 6 Alkoxy, C 1 ~C 6 Haloalkoxy, (C 1 ~C 6 Alkoxy)C 1 ~C 6 Alkyl and -O(C 1 ~C 6 Alkoxy)C 1 ~C 6 In some embodiments, each Q is independently selected from the group consisting of -F, -Cl, -Br, -CH 3 , -CH 2 CH 3 , -CF 3 , -CH 3 , -OCH 3 and -OCH 2 CH 3 are independently selected from the group consisting of:

[0012] In some embodiments of the compounds of Formula (I), B is [ka] In some embodiments, R xis hydrogen, C 1 ~C 6 In another embodiment, -NHR is an alkyl or amino protecting group. x There is no hydrogen in R x is a divalent amino protecting group. For example, R x teeth, [ka] It is.

[0013] In some embodiments of the compound of Formula (I), the compound is [ka] [ka] or a salt thereof, R 2 H, [ka] -C(=O)CH 2 CH 2 C(=O)OH or -C(=O)CH 2 CH 2 C(=O)NH 2 and [ka] are each optionally substituted with one substituent Q, where Q is -F, -Cl, -Br, -CH 3 , -CH 2 CH 3 , -CF 3 , -CH 3 , -OCH 3 and -OCH 2 CH 3 In a further embodiment, B is selected from the group consisting of: [ka] and R x -C(=O)Ph(Bz), -C(=O)CH 3(Ac) or -C(=O)CH(CH 3 ) 2 (iBu).

[0014] In another aspect of the present disclosure, disclosed herein is a method for preparing a synthetic oligonucleotide, comprising reacting a compound of formula (I) described herein with an oligonucleotide. In some embodiments, the oligonucleotide can have a length of 1-100 nucleobases. In some embodiments, the reaction can be carried out on a solid support, for example, a CPG solid support.

[0015] In another aspect of the disclosure, Structure of formula (II): [ka] (In the formula, X is O or S; R 4 H, unsubstituted C 1 ~C 6 Alkyl or substituted C 1 ~C 6 is alkyl, B is a natural nucleobase, a modified natural nucleobase or a non-natural nucleobase; R Het is an optionally substituted 5-10 membered heteroaryl or an optionally substituted 5-10 membered heterocyclyl. 1. A method for deprotecting an oligonucleotide or polynucleotide comprising at least one 2' protected nucleotide residue, comprising: Disclosed herein are methods that include contacting an oligonucleotide or polynucleotide with a composition that includes an amine (e.g., a primary amine) or ammonia to deprotect a 2' protected nucleotide residue.

[0016] A further aspect of the present disclosure relates to an oligonucleotide or polynucleotide prepared by the methods described herein.

[0017] Yet another aspect of the present disclosure is a method for producing a method for manufacturing a semiconductor device comprising the steps of: Structure of formula (II): [ka] and a polynucleotide having at least one 2' protected nucleotide residue, comprising: X is O or S; R 4 H, unsubstituted C 1 ~C 6 Alkyl or substituted C 1 ~C 6 is alkyl, B is a natural nucleobase, a modified natural nucleobase or a non-natural nucleobase; R Het is an optionally substituted 5-10 membered heteroaryl or an optionally substituted 5-10 membered heterocyclyl. [Brief description of the drawings]

[0018] [Figure 1] FIG. 1 is a general reaction scheme for the preparation of 2' nucleoside phosphoramidites, where an --O-phosphoramidite is present at the 3' position according to an embodiment of the present application. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0019] Detailed Description The compounds disclosed herein relate to nucleoside phosphoramidites that have a novel protecting group at the 2' position of the ribose moiety.In some embodiments, the 2'-protected nucleoside phosphoramidite compounds disclosed herein can facilitate the easy removal of protecting groups without the use of harsh conditions or toxic metal reagents, and can also reduce / eliminate the undesired 2' to 3' migration of protecting groups.In some embodiments, the 2'-protected nucleoside phosphoramidite compounds disclosed herein can improve the yield and efficiency of RNA synthesis.

[0020] definition Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by those skilled in the art. All patents, applications, published applications and other publications mentioned herein are incorporated by reference in their entirety unless otherwise stated. In the event that there is a plurality of definitions for a term herein, the definition in this section shall prevail unless otherwise stated. As used in this specification and the appended claims, the singular forms "a", "an" and "the" include plural referents unless the context clearly dictates otherwise. Conventional methods of mass spectroscopy, NMR, HPLC, protein chemistry, biochemistry, recombinant DNA techniques and pharmacology are used unless otherwise indicated. The use of "or" or "and" means "and / or" unless otherwise stated. Additionally, the use of the term "including" as well as other forms such as "include", "includes" and "included" is not limiting.

[0021] Although the present disclosure has been illustrated and described in detail above, such description should be considered as illustrative or exemplary, and not restrictive. The present disclosure is not limited to the disclosed embodiments. Variations to the disclosed embodiments can be understood and made by those skilled in the art from a consideration of the present disclosure and the appended claims, and upon practice of the claimed disclosure.

[0022] All references cited herein are incorporated herein by reference in their entirety. To the extent that publications and patents or patent applications incorporated by reference conflict with the disclosure contained herein, the present specification is intended to supersede and / or supersede any such conflicting material.

[0023] Unless otherwise defined, all terms (including technical and scientific terms) should be given their ordinary and customary meaning to one of ordinary skill in the art and should not be limited to any special or customary meaning unless expressly so defined herein. It should be noted that when describing certain features or embodiments of the present disclosure, the use of a particular terminology should not be construed as implying that the terminology has been redefined herein to be limited to include every specific feature of the feature or embodiment of the present disclosure to which the terminology pertains.

[0024] When a range of values ​​is presented, it is understood that the upper and lower limits, as well as every intervening value between the upper and lower limits of the range, are encompassed within the scope of an embodiment.

[0025] As used herein, any "R" group represents a substituent that may be attached to the indicated atom. The R group may be substituted or unsubstituted. When two "R" groups are described as "together," the R groups and the atom to which they are attached may form a cycloalkyl, aryl, heteroaryl, or heterocyclic ring. For example, but not limited to, R a and R b When a ring structure is shown as being "together" or "bonded together," it means that they are covalently bonded to one another to form a ring: [ka] This means forming

[0026] Whenever a group is described as "optionally substituted," the group can be unsubstituted or substituted with one or more of the indicated substituents. Similarly, when a group is described as "substituted," the substituents can be selected from one or more of the indicated substituents. If no substituents are indicated, the indicated "optionally substituted" or "substituted" group can be any group, including alkyl (e.g., C 1 ~C 6 alkyl); alkenyl (e.g., C 2 ~C 6 alkenyl); alkynyl (e.g., C 2 ~C 6 alkynyl);C 3 ~C 8 Carbocyclyl (e.g., C 3 ~C 8 Cycloalkyl, C 3 ~C 8 Cycloalkenyl or C 3 ~C 8 It is also intended that the alkynyl group may be one or more groups individually and independently selected from cycloalkynyl, each of which may further include, for example, halo, C 1 ~C 6 Alkyl, C 1 ~C 6 Alkoxy, C 1 ~C 6 Haloalkyl, C 1 ~C 6 Haloalkoxy, Hydroxy (C 1 ~C 6 Alkyl), (C 1 ~C 6 Alkoxy)C 1 ~C 6 Alkyl or -O(C 1 ~C 6 Alkoxy)C 1 ~C 6 alkyl);(C 3 ~C 7 Carbocyclyl)C 1 ~C 6 Alkyl (which may further include, for example, halo, C 1 ~C 6Alkyl, C 1 ~C 6 Alkoxy, C 1 ~C 6 Haloalkyl, C 1 ~C 6 Haloalkoxy, Hydroxy (C 1 ~C 6 Alkyl), (C 1 ~C 6 Alkoxy)C 1 ~C 6 Alkyl or -O(C 1 ~C 6 Alkoxy)C 1 ~C 6 alkyl); 5-10 membered heterocyclyl (which may further be substituted, for example, with halo, C 1 ~C 6 Alkyl, C 1 ~C 6 Alkoxy, C 1 ~C 6 Haloalkyl, C 1 ~C 6 Haloalkoxy, Hydroxy (C 1 ~C 6 Alkyl), (C 1 ~C 6 Alkoxy)C 1 ~C 6 Alkyl or -O(C 1 ~C 6 Alkoxy)C 1 ~C 6 (5-10 membered heterocyclyl)C 1 ~C 6 Alkyl (which may further include, for example, halo, C 1 ~C 6 Alkyl, C 1 ~C 6 Alkoxy, C 1 ~C 6 Haloalkyl, C 1 ~C 6 Haloalkoxy, Hydroxy (C 1 ~C 6 Alkyl), (C 1 ~C 6 Alkoxy)C 1 ~C6 Alkyl or -O(C 1 ~C 6 Alkoxy)C 1 ~C 6 alkyl, optionally substituted; aryl, which may further be substituted, for example, by halo, 1 ~C 6 Alkyl, C 1 ~C 6 Alkoxy, C 1 ~C 6 Haloalkyl, C 1 ~C 6 Haloalkoxy, Hydroxy (C 1 ~C 6 Alkyl), (C 1 ~C 6 Alkoxy)C 1 ~C 6 Alkyl or -O(C 1 ~C 6 Alkoxy)C 1 ~C 6 (aryl)C 1 ~C 6 Alkyl (which may further include, for example, halo, C 1 ~C 6 Alkyl, C 1 ~C 6 Alkoxy, C 1 ~C 6 Haloalkyl, C 1 ~C 6 Haloalkoxy, Hydroxy (C 1 ~C 6 Alkyl), (C 1 ~C 6 Alkoxy)C 1 ~C 6 Alkyl or -O(C 1 ~C 6 Alkoxy)C 1 ~C 6 alkyl; 5-10 membered heteroaryl, which may further be substituted with halo, 1 ~C 6 Alkyl, C 1 ~C 6 Alkoxy, C 1 ~C 6Haloalkyl, C 1 ~C 6 Haloalkoxy, Hydroxy (C 1 ~C 6 Alkyl), (C 1 ~C 6 Alkoxy)C 1 ~C 6 Alkyl or -O(C 1 ~C 6 Alkoxy)C 1 ~C 6 (5-10 membered heteroaryl)C 1 ~C 6 Alkyl (which can further include halo, C 1 ~C 6 Alkyl, C 1 ~C 6 Alkoxy, C 1 ~C 6 Haloalkyl, C 1 ~C 6 Haloalkoxy, Hydroxy (C 1 ~C 6 Alkyl), (C 1 ~C 6 Alkoxy)C 1 ~C 6 Alkyl or -O(C 1 ~C 6 Alkoxy)C 1 ~C 6 alkyl (optionally substituted); halo (e.g., fluoro, chloro, bromo, iodo); cyano; hydroxy; protected hydroxy; alkoxy (e.g., C 1 ~C 6 alkoxy); haloalkyl (e.g., -CF 3 C etc. 1 ~C 6 haloalkyl; haloalkyl (e.g., -OCF 3 C etc. 1 ~C 6 haloalkoxy);(C 1 ~C 6 Alkoxy)C 1 ~C 6 Alkyl; -O(C 1 ~C 6 Alkoxy)C1 ~C 6 Alkyl; (C 1 ~C 6 Haloalkoxy)C 1 ~C 6 Alkyl; -O(C 1 ~C 6 Haloalkoxy)C 1 ~C 6 Alkyl; aryloxy; sulfhydryl (mercapto); alkylthio (e.g., C 1 ~C 6 alkylthio;arylthio;azide;nitro;O-carbamyl;N-carbamyl;O-thiocarbamyl;N-thiocarbamyl;C-amido;N-amido;S-sulfonamido;N-sulfonamido;C-carboxy;protected C-carboxy;O-carboxy;acyl;cyanate;isocyanato;thiocyanato;isothiocyanato;silyl;sulfenyl;sulfinyl;sulfonyl;trihalomethanesulfonyl;trihalomethanesulfonamido;amino (including protected derivatives thereof);monosubstituted amino (e.g., NH(C 1 ~C 6 alkyl; disubstituted amino (e.g., N(C 1 ~C 6 Alkyl) 2 );oxo (=O); and thioxo (=S) as appropriate.

[0027] As used herein, "C" refers to a set of integers where "a" and "b" are integers. a ~C b " refers to the number of carbon atoms in an alkyl group, or the number of ring atoms in a cycloalkyl, aryl, heteroaryl, or heterocyclyl group. That is, the alkyl, cycloalkyl ring, and aryl ring can contain from "a" to "b" (inclusive) carbon atoms. Similarly, the heteroaryl ring and heterocyclyl ring can contain from "a" to "b" (inclusive) total ring atoms. Thus, for example, "C 1 ~C 4 An "alkyl" group is any alkyl group having 1 to 4 carbons, i.e., CH 3 -, CH3 CH 2 -, CH 3 CH 2 CH 2 -, (CH 3 ) 2 CH-, CH 3 CH 2 CH 2 CH 2 -, CH 3 CH 2 CH(CH 3 )- and (CH 3 ) 3 C-. 3 ~C 4 Cycloalkyl groups refer to all cycloalkyl groups having 3 to 4 carbon atoms, i.e., cyclopropyl and cyclobutyl. Similarly, a "4- to 6-membered heterocyclyl" group refers to all heterocyclyl groups having 4 to 6 total ring atoms, such as azetidine, oxetane, oxazoline, pyrrolidine, piperidine, piperazine, morpholine, and the like. When "a" and "b" are not specified for an alkyl, cycloalkyl, aryl, heteroaryl, or heterocyclyl group, the broadest range described in these definitions should be considered. As used herein, the term "C 1 ~C 6 " is C 1 , C 2 , C 3 , C 4 , C 5 and C 6 , as well as the range defined by either of two numbers. For example, C 1 ~C 6 Alkyl is C 1 , C 2 , C 3 , C 4 , C 5 and C 6 Alkyl, C 2 ~C 6 Alkyl, C 1 ~C 3 Alkyl, etc. Similarly, C 3 ~C 8Carbocyclyl or cycloalkyl are hydrocarbon rings containing 3, 4, 5, 6, 7 and 8 carbon atoms, respectively, or C 3 ~C 7 Cycloalkyl or C 5 ~C 6 It includes ranges defined by either of two numbers, such as cycloalkyl.

[0028] As used herein, "alkyl" refers to straight or branched chain hydrocarbons, including fully saturated (no double or triple bonds) hydrocarbon groups. The alkyl group can have 1 to 20 carbon atoms (wherever an alkyl group appears herein, a numerical range such as "1 to 20" refers to each integer in the given range; for example, "1 to 20 carbon atoms" means that the alkyl group can consist of 1 carbon atom, 2 carbon atoms, 3 carbon atoms, etc., up to and including 20 carbon atoms, but the definition herein also encompasses occurrences of the term "alkyl" where no numerical range is specified). The alkyl group can also be a medium-sized alkyl, having 1 to 10 carbon atoms. The alkyl group can also be a lower alkyl, having 1 to 6 carbon atoms. The alkyl group of the compound can be a "C 1 ~C 4 By way of example only, "C 1 ~C 4 "Alkyl" indicates that there are from 1 to 4 carbon atoms in the alkyl chain, i.e., the alkyl chain is selected from methyl, ethyl, propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl, and t-butyl. Typical alkyl groups include, but are in no way limited to, methyl, ethyl, n-propyl, isopropyl, butyl, isobutyl, tertiary butyl, pentyl (straight chain or branched), and hexyl (straight chain or branched). The alkyl groups may be substituted or unsubstituted.

[0029] As used herein, "alkenyl" refers to a straight or branched chain hydrocarbon containing one or more double bonds. Alkenyl groups may have from 2 to 20 carbon atoms. By way of example only, "C 2 ~C 6 "Alkenyl" indicates that there are 2 to 6 carbon atoms in the alkenyl chain, i.e., the alkenyl chain is selected from the group consisting of ethenyl, propen-1-yl, propen-2-yl, propen-3-yl, buten-1-yl, buten-2-yl, buten-3-yl, buten-4-yl, 1-methyl-propen-1-yl, 2-methyl-propen-1-yl, 1-ethyl-ethen-1-yl, 2-methyl-propen-3-yl, buta-1,3-dienyl, buta-1,2,-dienyl, and buta-1,2-dien-4-yl. Exemplary alkenyl groups include, but are in no way limited to, ethenyl, propenyl, butenyl, pentenyl, and hexenyl. The alkenyl group may be substituted or unsubstituted.

[0030] As used herein, "alkynyl" refers to a straight or branched chain hydrocarbon containing one or more triple bonds. Alkynyl groups may have from 2 to 20 carbon atoms. By way of example only, "C 2 ~C 4 "Alkynyl" indicates that there are 2 to 6 carbon atoms in the alkynyl chain, i.e., the alkynyl chain is selected from the group consisting of ethynyl, propyn-1-yl, propyn-2-yl, butyn-1-yl, butyn-3-yl, butyn-4-yl, and 2-butynyl. Typical alkynyl groups include, but are in no way limited to, ethynyl, propynyl, butynyl, pentynyl, hexynyl, and the like. The alkynyl group may be substituted or unsubstituted.

[0031] As used herein, "cycloalkyl" refers to a fully saturated (no double or triple bonds), monocyclic or polycyclic hydrocarbon ring system. When composed of two or more rings, the rings may be joined together in a fused, bridged or spiro fashion. As used herein, the term "fused" refers to two rings that have two atoms and one bond in common. As used herein, the term "bridged cycloalkyl" refers to a compound in which the cycloalkyl contains a linkage of one or more atoms connecting non-adjacent atoms. As used herein, the term "spiro" refers to two rings that have one atom in common, and the two rings are not connected by a bridge. Cycloalkyl groups can contain 3-10 atoms in the ring, 3-8 atoms in the ring, or 3-6 atoms in the ring. Cycloalkyl groups can be unsubstituted or substituted. Examples of monocyclic cycloalkyl groups include, but are in no way limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl. Examples of bicyclic fused cycloalkyl groups are decahydronaphthalenyl, dodecahydro-1H-phenalenyl, and tetradecahydroanthracenyl. Examples of bicyclic bridged cycloalkyl groups are bicyclo[1.1.1]pentyl, adamantanyl, and norbornanyl. Examples of bicyclic spirocycloalkyl groups include spiro[3.3]heptane and spiro[4.5]decane.

[0032] As used herein, "carbocyclyl" refers to a non-aromatic monocyclic or polycyclic hydrocarbon ring system. When the ring is composed of two or more rings, they may be joined together in a fused, bridged or spiro fashion, as described herein. A carbocyclyl group can contain 3-30 atoms in the ring, 3-20 atoms in the ring, 3-10 atoms in the ring, 3-8 atoms in the ring, or 3-6 atoms in the ring. A carbocyclyl group may be unsubstituted or substituted. Examples of carbocyclyl groups include, but are in no way limited to, the non-aromatic moieties of cycloalkyl groups as defined herein, 1,2,3,4-tetrahydronaphthalene, 2,3-dihydro-1H-indene, 5,6,7,8-tetrahydroquinoline, and 6,7-dihydro-5H-cyclopenta[b]pyridine.

[0033] As used herein, "aryl" refers to a carbocyclic (all carbon) monocyclic or polycyclic aromatic ring system (including fused ring systems in which two carbocyclic rings share a chemical bond) having a completely delocalized pi-electron system throughout the ring. The number of carbon atoms in an aryl group can vary. For example, an aryl group can be C 6 Aryl group or C 10 It can be an aryl group. Examples of aryl groups include, but are not limited to, benzene and naphthalene. The aryl group can be substituted or unsubstituted.

[0034] As used herein, "heteroaryl" refers to a monocyclic or polycyclic aromatic ring system (a ring system having a fully delocalized pi-electron system) containing one or more heteroatoms (e.g., 1, 2, or 3 heteroatoms), which are elements other than carbon, including, but not limited to, nitrogen, oxygen, and sulfur. The number of atoms in the ring of a heteroaryl group can vary. For example, a heteroaryl group can contain 5-10 atoms in the ring, 6-10 atoms in the ring, or 5-6 atoms in the ring, such as 9 carbon atoms and 1 heteroatom; 8 carbon atoms and 2 heteroatoms; 7 carbon atoms and 3 heteroatoms; 8 carbon atoms and 1 heteroatom; 7 carbon atoms and 2 heteroatoms; 6 carbon atoms and 3 heteroatoms; 5 carbon atoms and 4 heteroatoms; 5 carbon atoms and 1 heteroatom; 4 carbon atoms and 2 heteroatoms; 3 carbon atoms and 3 heteroatoms; 4 carbon atoms and 1 heteroatom; 3 carbon atoms and 2 heteroatoms; or 2 carbon atoms and 3 heteroatoms. Additionally, the term "heteroaryl" includes fused ring systems in which two rings, such as at least one aryl ring and at least one heteroaryl ring or at least two heteroaryl rings, share at least one chemical bond. Examples of heteroaryl rings include, but are not limited to, furan, furazan, thiophene, benzothiophene, phthalazine, pyrrole, oxazole, benzoxazole, 1,2,3-oxadiazole, 1,2,4-oxadiazole, thiazole, 1,2,3-thiadiazole, 1,2,4-thiadiazole, benzothiazole, imidazole, benzimidazole, indole, indazole, pyrazole, benzopyrazole, isoxazole, benzisoxazole, isothiazole, triazole, benzotriazole, thiadiazole, tetrazole, pyridine, pyridazine, pyrimidine, pyrazine, purine, pteridine, quinoline, isoquinoline, quinazoline, quinoxaline, cinnoline, and triazine. A heteroaryl group can be substituted or unsubstituted.

[0035] As used herein, "heterocyclyl" refers to 3-, 4-, 5-, 6-, 7-, 8-, 9-, and 10-membered monocyclic, bicyclic, and tricyclic ring systems, in which the carbon atoms, together with one to five heteroatoms, constitute said ring system. Heterocycles can optionally contain one or more unsaturated bonds positioned in such a manner, but there is no fully delocalized pi-electron system throughout the ring (i.e., the heterocyclyl group is not aromatic). Heteroatoms are elements other than carbon, including, but not limited to, oxygen, sulfur, and nitrogen. Heterocycles may further contain one or more carbonyl functionalities, such that the definition includes oxo systems, such as lactams, lactones, and cyclic carbamates. When composed of two or more rings, the rings may be joined together in a fused, bridged, or spiro fashion. As used herein, the term "fused" refers to two rings having two atoms and one bond in common. As used herein, the term "bridged heterocyclyl" refers to a compound in which the heterocyclyl contains a linkage of one or more atoms connecting non-adjacent atoms. As used herein, the term "spiro" refers to two rings having one atom in common, where the two rings are not connected by a bridge. Heterocyclyl groups can contain 3-10 atoms in the ring, 3-8 atoms in the ring, 3-6 atoms in the ring, or 5-6 atoms in the ring. For example, 5 carbon atoms and 1 heteroatom; 4 carbon atoms and 2 heteroatoms; 3 carbon atoms and 3 heteroatoms; 4 carbon atoms and 1 heteroatom; 3 carbon atoms and 2 heteroatoms; 2 carbon atoms and 3 heteroatoms; 1 carbon atom and 4 heteroatoms; 3 carbon atoms and 1 heteroatom; or 2 carbon atoms and 1 heteroatom. Additionally, any nitrogen in a heterocyclyl group may be quaternized. A heterocyclyl group may be linked to the remainder of the molecule through a carbon atom in the heterocyclyl group (C-linked) or by a heteroatom in the heterocyclyl group, such as a nitrogen atom (N-linked). A heterocyclyl group may be unsubstituted or substituted.Examples of such "heterocyclyl" groups include, but are not limited to, aziridine, oxirane, thiirane, azetidine, oxetane, 1,3-dioxine, 1,3-dioxane, 1,4-dioxane, 1,2-dioxolane, 1,3-dioxolane, 1,4-dioxolane, 1,3-oxathiane, 1,4-oxathiine, 1,3-oxathiolane, 1,3-dithiol, 1,3-dithiolane, 1,4-oxathiane, tetrahydro-1,4-thiazine, 2H-1,2-oxazine, maleimide, succinimide, barbituric acid, thiobarbituric acid, dioxopiperazine, hydantoin, dihydrouracil, trioxane, hexahydro-1,3,5-triazine, tetrahydro-1,4-thiazine, 2H-1,2-oxazine, tetrahydro-1,4-thi ... Examples of suitable amines include amines such as phenyl, ... Examples of spiroheterocyclyl groups include 2-azaspiro[3.3]heptane, 2-oxaspiro[3.3]heptane, 2-oxa-6-azaspiro[3.3]heptane, 2,6-diazaspiro[3.3]heptane, 2-oxaspiro[3.4]octane, and 2-azaspiro[3.4]octane.

[0036] As used herein, "alkylene" refers to a branched or straight-chain, fully saturated diradical chemical group containing only carbon and hydrogen attached to the remainder of the molecule through two points of attachment. 1 ~C 10 "Alkylene" indicates that there are 1 to 10 carbon atoms in the alkylene chain. Non-limiting examples include ethylene (-CH 2 CH 2 -), propylene (-CH2 CH 2 CH 2 -), butylene (-CH 2 CH 2 CH 2 CH 2 -) and pentylene (-CH 2 CH 2 CH 2 CH 2 CH 2 -) are mentioned.

[0037] As used herein, "alkenylene" refers to a straight or branched chain diradical chemical group that contains only carbon and hydrogen and contains at least one carbon-carbon double bond that is attached to the rest of the molecule through two points of attachment. An alkenylene group is defined as "C 2 ~C 10 Alkenylene" or similar designations. By way of example only, "C 2 ~C 10 "Alkenylene" means that there are 2 to 10 carbon atoms in the alkenylene chain.

[0038] As used herein, "alkynylene" refers to a straight or branched chain diradical chemical group that contains only carbon and hydrogen and contains at least one carbon-carbon triple bond, which is attached to the rest of the molecule through two points of attachment. An alkynylene group is defined as "C 2 ~C 10 Alkenylene" or similar designations. By way of example only, "C 2 ~C 10 "Alkynylene" indicates that there are 2 to 10 carbon atoms in the alkynylene chain.

[0039] As used herein, "heteroalkylene" refers to an alkylene group, as defined herein, that contains one or more heteroatoms in its carbon backbone (i.e., an alkylene group in which one or more carbon atoms have been replaced by a heteroatom, such as a nitrogen, oxygen, or sulfur atom). For example, -CH 2- may be replaced by -O-, -S-, or -NH-. Heteroalkylene groups include, but are not limited to, ether, thioether, amino-alkylene, and alkylene-amino-alkylene moieties. In some embodiments, heteroalkylene contains one, two, three, four, or five -CH 2 CH 2 Alternatively and / or in addition, one or more carbon atoms can also be replaced by oxo (=O) to give a carbonyl, e.g., -CH 2 - may be replaced by -C(=O)-.

[0040] As used herein, "aralkyl" and "(aryl)alkyl" refer to an aryl group, as defined above, linked through an alkylene group as a substituent. The alkylene and aryl groups of the aralkyl may be substituted or unsubstituted. Examples include, but are not limited to, benzyl, 2-phenylalkyl, 3-phenylalkyl, and naphthylalkyl. In some embodiments, the alkylene is an unsubstituted straight chain containing 1, 2, 3, 4, 5, or 6 methylene units.

[0041] As used herein, "heteroaralkyl" and "(heteroaryl)alkyl" refer to a heteroaryl group, as defined above, linked via an alkylene group, as a substituent, as defined above. The alkylene and heteroaryl groups of the heteroaralkyl may be substituted or unsubstituted. Examples include, but are not limited to, 2-thienylalkyl, 3-thienylalkyl, furylalkyl, thienylalkyl, pyrrolylalkyl, pyridylalkyl, isoxazolylalkyl, and imidazolylalkyl and their benzo-fused analogs. In some embodiments, the alkylene is an unsubstituted straight chain containing 1, 2, 3, 4, 5, or 6 methylene units.

[0042] As used herein, "(heterocyclyl)alkyl" refers to a heterocyclic or heterocyclyl group as defined above linked through an alkylene group as a substituent, as defined above. The alkylene and heterocyclyl groups of (heterocyclyl)alkyl may be substituted or unsubstituted. Examples include, but are not limited to, (tetrahydro-2H-pyran-4-yl)methyl, (piperidin-4-yl)ethyl, (piperidin-4-yl)propyl, (tetrahydro-2H-thiopyran-4-yl)methyl and (1,3-thiazinane-4-yl)methyl. In some embodiments, the alkylene is an unsubstituted straight chain containing 1, 2, 3, 4, 5 or 6 methylene units.

[0043] As used herein, "cycloalkylalkyl" and "(cycloalkyl)alkyl" refer to a cycloalkyl group (as defined herein) linked, as a substituent, through an alkylene group. Examples include, but are not limited to, cyclopropylmethyl, cyclobutylmethyl, cyclopentylethyl, and cyclohexylpropyl. In some embodiments, the alkylene is an unsubstituted straight chain containing 1, 2, 3, 4, 5, or 6 methylene units.

[0044] As used herein, "alkoxy" refers to the formula -OR, where R is an alkyl group as defined herein. A non-limiting list of alkoxy groups includes methoxy, ethoxy, n-propoxy, 1-methylethoxy (isopropoxy), n-butoxy, iso-butoxy, sec-butoxy, and tert-butoxy. The alkoxy may be substituted or unsubstituted.

[0045] As used herein, "haloalkyl" refers to an alkyl group in which one or more of the hydrogen atoms are replaced by halogen (e.g., mono-haloalkyl, di-haloalkyl and tri-haloalkyl). Such groups include, but are not limited to, chloromethyl, fluoromethyl, difluoromethyl, trifluoromethyl and 1-chloro-2-fluoromethyl, 2-fluoroisobutyl. Haloalkyl may be substituted or unsubstituted.

[0046] As used herein, "haloalkoxy" refers to an alkoxy group in which one or more of the hydrogen atoms are replaced by halogen (e.g., mono-haloalkoxy, di-haloalkoxy and tri-haloalkoxy). Such groups include, but are not limited to, chloromethoxy, fluoromethoxy, difluoromethoxy, trifluoromethoxy and 1-chloro-2-fluoromethoxy, 2-fluoroisobutoxy. Haloalkoxy may be substituted or unsubstituted.

[0047] As used herein, "amino" refers to -NH 2 The term "monosubstituted amino group," as used herein, refers to an amino (-NH) group in which one of the hydrogen atoms has been replaced by a substituent. 2 The term "disubstituted amino group," as used herein, refers to an amino (-NH) group in which each of the two hydrogen atoms is replaced by a substituent. 2 The term "optionally substituted amino" as used herein refers to the -NR A R B R refers to the group A and R B is independently hydrogen, alkyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, aralkyl, or heterocyclyl(alkyl), as defined herein.

[0048] As used herein, "alkylamino" or "(alkyl)amino" refers to -NR A R B R refers to the group A and R B is hydrogen or alkyl as defined above, R A and R B At least one of the alkyl groups is alkyl. The alkyl portion of the (alkyl)amine may, for example, be 1 ~C 6 Examples of such groups include alkyl groups.

[0049] As used herein, “aminoalkyl” or “(amino)alkyl” refers to an alkyl group in which one or more of the hydrogen atoms is replaced by an amino group or “—NR A R B The alkyl portion of an aminoalkyl may, for example, be a C 1 ~C 6 Examples of such alkyl groups include alkyl.

[0050] The terms "halogen atom" or "halogen," as used herein, mean any one of the radio-stable atoms in column 7 of the periodic table of the elements, such as fluorine, chlorine, bromine and iodine.

[0051] As used herein, "alkoxyalkyl" or "(alkoxy)alkyl" refers to any alkyl group selected from the group consisting of C 2 ~C 8 Alkoxyalkyl or (C 1 ~C 6 Alkoxy)C 1 ~C 6 Alkoxy groups linked via an alkylene group such as alkyl, e.g., -(CH 2 ) 1~3 -OCH 3 Refers to...

[0052] As used herein, “—O-alkoxyalkyl” or “—O-(alkoxy)alkyl” refers to an —O—(C 1~C 6 Alkoxy)C 1 ~C 6 Alkoxy groups linked via an -O-(alkylene) group such as alkyl, e.g., -O-(CH 2 ) 1~3 -OCH 3 Refers to...

[0053] As used herein, "aryloxy" and "arylthio" refer to RO- and RS-, where R is aryl as defined above, such as, but not limited to, phenyl. Both aryloxy and arylthio may be substituted or unsubstituted.

[0054] A "sulfenyl" group refers to the "-SR" group, where R can be hydrogen, alkyl, alkenyl, alkynyl, carbocyclyl, aryl, heteroaryl, heterocyclyl, aralkyl, or heterocyclyl(alkyl), as defined above. Sulfenyl can be substituted or unsubstituted.

[0055] A "sulfinyl" group refers to a "-S(=O)-R" group, where R can be the same as defined for sulfenyl. Sulfinyl can be substituted or unsubstituted.

[0056] A "sulfonyl" group refers to a group in which R can be the same as defined for sulfenyl, such as "SO 2 R" group. The sulfonyl may be substituted or unsubstituted.

[0057] An "O-carboxy" group refers to an "RC(=O)O-" group, where R can be hydrogen, alkyl, alkenyl, alkynyl, carbocyclyl, aryl, heteroaryl, heterocyclyl, aralkyl, or heterocyclyl(alkyl), as defined herein. O-carboxy can be substituted or unsubstituted.

[0058] The terms "ester" and "C-carboxy" refer to the group "-C(=O)OR" where R can be the same as defined for O-carboxy. Ester or C-carboxy can be substituted or unsubstituted.

[0059] A "trihalomethanesulfonyl" group is a group in which X is a halogen. 3 CSO 2 -" group.

[0060] A "trihalomethanesulfonamido" group refers to a "X" group, where X is a halogen and R is hydrogen, alkyl, alkenyl, alkynyl, carbocyclyl, aryl, heteroaryl, heterocyclyl, aralkyl, or heterocyclyl(alkyl), as defined herein. 3 CS(O) 2 It refers to the "N(R)-" group.

[0061] A "mercapto" group refers to a "-SH" group.

[0062] An "S-sulfonamide" group is R A and R B may be independently hydrogen, alkyl, alkenyl, alkynyl, carbocyclyl, aryl, heteroaryl, heterocyclyl, aralkyl, or heterocyclyl(alkyl), as defined herein; 2 N(R A R B )" group. S-sulfonamides can be substituted or unsubstituted.

[0063] An "N-sulfonamide" group is one selected from R and R A may be independently hydrogen, alkyl, alkenyl, alkynyl, carbocyclyl, aryl, heteroaryl, heterocyclyl, aralkyl, or heterocyclyl(alkyl), as defined herein. 2 N(R A)-" group. N-Sulfonamides may be substituted or unsubstituted.

[0064] An "O-carbamyl" group is R A and R B may be the same as defined for S-sulfonamides, "-OC(=O)N(R A R B )" group. O-Carbamyl may be substituted or unsubstituted.

[0065] An "N-carbamyl" group is a group consisting of R and R A may be the same as defined for N-sulfonamides, "ROC(=O)N(R A )-" group. N-Carbamyl may be substituted or unsubstituted.

[0066] An "O-thiocarbamyl" group is R A and R B may be the same as defined for S-sulfonamides, "-OC(=S)-N(R A R B )" group. O-Thiocarbamyl may be substituted or unsubstituted.

[0067] An "N-thiocarbamyl" group is a group consisting of R and R A may be the same as defined for N-sulfonamides, "ROC(=S)N(R A )-" group. N-Thiocarbamyl may be substituted or unsubstituted.

[0068] A "C-amide" group is a group consisting of R A and R B may be the same as defined for S-sulfonamides, "-C(=O)N(R A R B )" group. C-amides can be substituted or unsubstituted.

[0069] An "N-amide" group is one in which R and R A may be the same as defined for N-sulfonamides, "RC(=O)N(R A N-amides refer to a "—" group. N-amides can be substituted or unsubstituted.

[0070] When the number of substituents is not specified (e.g., haloalkyl), one or more substituents may be present. For example, "haloalkyl" can include one or more of the same or different halogens.

[0071] In any of the compounds described herein that have one or more chiral centers, if the absolute stereochemistry is not explicitly indicated, it is understood that each center can be independently R or S configuration, or a mixture thereof. Thus, the compounds provided herein can be enantiomerically pure, enantiomerically enriched, or stereoisomeric mixtures, including all diastereomeric forms and enantiomers. Furthermore, in any of the compounds described herein that have one or more double bonds that result in geometric isomers that can be defined as E or Z, it is understood that each double bond can be independently E or Z, or a mixture thereof. Stereoisomers can be obtained, if desired, by methods such as stereoselective synthesis and / or separation of stereoisomers by chiral chromatographic columns. Similarly, it is understood that in any of the compounds described, all tautomeric forms are also intended to be included.

[0072] Whenever a substituent is depicted as a diradical (i.e., having two points of attachment to the rest of the molecule), it is to be understood that the substituent may be attached in any orientation unless otherwise indicated. Thus, for example, -AE- or [ka] Substituents depicted as: include those oriented such that A is attached at the leftmost attachment point of the molecule, as well as those where A is attached at the rightmost attachment point of the molecule. Additionally, groups or substituents may be [ka] and when L is defined as a bond or is absent, such a group or substituent is [ka] is equivalent to

[0073] Where the compounds disclosed herein utilize unsatisfied valences, it is to be understood that the valences should be filled with hydrogen and / or deuterium.

[0074] It is understood that the compounds described herein can be labeled by isotopes or by other means, including but not limited to the use of chromophores or fluorescent moieties, bioluminescent labels or chemiluminescent labels. Substitution with isotopes such as deuterium may provide certain therapeutic advantages due to greater metabolic stability, such as increased in vivo half-life or reduced dosage requirements. Each chemical element represented in a compound structure can include any isotope of said element. For example, in a compound structure, it is understood that a hydrogen atom may be explicitly disclosed or present in the compound. In any position of a compound where a hydrogen atom may be present, the hydrogen atom can be any isotope of hydrogen, including but not limited to hydrogen-1 (protium), hydrogen-2 (deuterium) and hydrogen-3 (tritium). Thus, when referring to a compound herein, all possible isotopic forms are included unless the context clearly dictates otherwise.

[0075] Similarly, it is understood that the compounds described herein, such as the compounds of the preferred embodiments, include the compounds in any of the forms described herein (e.g., pharma- ceutically acceptable salts, crystalline forms, amorphous forms, solvate forms, enantiomers, tautomeric forms, etc.).

[0076] As used herein, abbreviations for all protecting groups, amino acids and other compounds follow their common usage, recognized abbreviations, or the IUPAC-IUB Commission on Biochemical Nomenclature (see Biochem. 11:942-944 (1972)), unless otherwise indicated.

[0077] The term "protecting group(s)" as used herein refers to any atom or group of atoms added to a molecule to prevent a group present in the molecule from undergoing an undesired chemical reaction. Examples of protecting group moieties are described in TW Greene and PGM Wuts, Protective Groups in Organic Synthesis, 3. Ed. John Wiley & Sons, 1999 and JFW McOmie, Protective Groups in Organic Chemistry Plenum Press, 1973, both of which are incorporated herein by reference for the limited purpose of disclosing suitable protecting groups. Protecting group moieties can be selected such that they are stable to certain reaction conditions and are easily removed at a convenient stage using methodologies known in the art. A non-limiting list of protecting groups includes benzyl (Bn); substituted benzyl; alkylcarbonyl (e.g., t-butoxycarbonyl (BOC), acetyl (i.e., -C(=O)CH 3or Ac) or isobutyryl (iBu); arylalkylcarbonyl (e.g., benzyloxycarbonyl or benzoyl (i.e., -C(=O)Ph or Bz)); substituted methyl ethers (e.g., methoxymethyl ether (MOM)); substituted ethyl ethers (e.g., methoxyethyl ether (MOE)); substituted benzyl ethers; tetrahydropyranyl ethers; silyl ethers (e.g., trimethylsilyl (TMS), triethylsilyl, triisopropylsilyl, t-butyldimethylsilyl (TBDMS), tri-iso-propylsilyloxymethyl (TOM) or t-butyldiphenylsilyl); esters (e.g., benzoate esters); carbonates (e.g., methoxymethyl carbonate); sulfonates (e.g., tosylates or mesylates); acyclic ketals (e.g., dimethyl acetal); cyclic ketals (e.g., 1,3-dioxane or 1,3-dioxolane); acyclic acetals; cyclic acetals; acyclic hemiacetals; cyclic hemiacetals; cyclic dithioketals (e.g., 1,3-dithiane or 1,3-dithiolane); and triarylmethyl groups (e.g., trityl; monomethoxytrityl (MMTr); 4,4'-dimethoxytrityl (DMTr); or 4,4',4"-trimethoxytrityl (TMTr)).

[0078] Examples of hydroxy protecting groups include, but are not limited to, acetyl, t-butyl, t-butoxymethyl, methoxymethyl, tetrahydropyranyl, 1-ethoxyethyl, 1-(2-chloroethoxy)ethyl, p-chlorophenyl, 2,4-dinitrophenyl, benzyl, 2,6-dichlorobenzyl, diphenylmethyl, p-nitrobenzyl, bis(2-acetoxyethoxy)methyl (ACE), 2-trimethylsilylethyl, trimethylsilyl, triethylsilyl, t-butyldimethylsilyl, t-butyldiphenylsilyl, triphenylsilyl, [(triisopropylsilyl)oxy]methyl. trimethylphenyl (TOM), benzoyl formate, chloroacetyl, trichloroacetyl, trifluoro-acetyl, pivaloyl, benzoyl, p-phenylbenzoyl, 9-fluorenylmethyl carbonate, mesylate, tosylate, triphenylmethyl (trityl), monomethoxytrityl, dimethoxytrityl (DMT), trimethoxytrityl, 1(2-fluorophenyl)-4-methoxypiperidin-4-yl (FPMP), 9-phenylxanthin-9-yl (Pixyl), and 9-(p-methoxyphenyl)xanthin-9-yl (MOX). More commonly used hydroxyl protecting groups include, but are not limited to, benzyl, 2,6-dichlorobenzyl, t-butyldimethylsilyl, t-butyldiphenylsilyl, benzoyl, mesylate, tosylate, dimethoxytrityl (DMT), 9-phenylxanthin-9-yl (pixyl), and 9-(p-methoxyphenyl)xanthin-9-yl (MOX).

[0079] Examples of protecting groups commonly used to protect phosphate and phosphorus hydroxy groups include, but are not limited to, methyl, ethyl, benzyl (Bn), phenyl, isopropyl, tert-butyl, allyl, cyclohexyl (cHex), pivaloyloxymethyl (-CH 2 -OC(=O)C(CH 3 ) 3, or POM), 4-methoxybenzyl, 4-chlorobenzyl, 4-nitrobenzyl, 4-acyloxybenzyl, 2-methylphenyl, 2,6-dimethylphenyl, 2-chlorophenyl, diphenylmethyl, 4-methylthio-1-butyl, 2-(S-acetylthio)ethyl (SATE), 2-cyanoethyl, 2-cyano-1,1-dimethylethyl (CDM), 4-cyano-2-butenyl, 2-(trimethylsilyl)ethyl (TSE), 2-(phenylthio)ethyl, 2-(triphenylsilyl) These include ethyl, 2-(benzylsulfonyl)ethyl, 2,2,2-trichloroethyl, 2,2,2-tribromoethyl, 2,3-dibromopropyl, 2,2,2-trifluoroethyl, thiophenyl, 2-chloro-4-tritylphenyl, 2-bromophenyl, 2-[N-isopropyl-N-(4-methoxybenzoyl)amino]ethyl, 4-(N-trifluoroacetylamino)butyl, 4-oxopentyl, 4-tritylaminophenyl, 4-benzylaminophenyl, and morpholino. The more commonly used phosphate and phosphorus protecting groups include, but are not limited to, methyl, ethyl, benzyl (Bn), phenyl, isopropyl, tert-butyl, 4-methoxybenzyl, 4-chlorobenzyl, 2-chlorophenyl, 2-cyanoethyl, and POM.

[0080] Examples of amino protecting groups include, but are not limited to, carbamate protecting groups such as 2-trimethylsilylethoxycarbonyl (Teoc), 1-methyl-1-(4-biphenylyl)ethoxycarbonyl (Bpoc), t-butoxycarbonyl (BOC), allyloxycarbonyl (Alloc), 9-fluorenylmethyloxycarbonyl (Fmoc), and benzyl-oxycarbonyl (Cbz); amide protecting groups such as formyl, acetyl, trihaloacetyl, benzoyl, and nitrophenylacetyl; sulfonamide protecting groups such as 2-nitrobenzenesulfonyl; and imine and cyclic imide protecting groups such as phthalimide and dithiasuccinoyl.

[0081] The term "leaving group," as used herein, refers to any atom or moiety that can be replaced by another atom or moiety in a chemical reaction. More specifically, in some embodiments, a "leaving group" refers to an atom or moiety that is displaced in a nucleophilic substitution reaction. In some embodiments, a "leaving group" is any atom or moiety that is the conjugate base of a strong acid. Examples of suitable leaving groups include, but are not limited to, tosylates and halogens. Non-limiting characteristics and examples of leaving groups can be found, for example, in Organic Chemistry, 2d ed., Francis Carey (1992), pages 328-331; Introduction to Organic Chemistry, 2d ed., Andrew Streitwieser and ClaytonHeathcock (1981), pages 169-171; and Organic Chemistry, 5 th ed., John McMurry (2000), pages 398 and 408, all of which are incorporated herein by reference for the limited purpose of disclosing characteristics and examples of leaving groups.

[0082] The term "pharmaceutical acceptable salt" as used herein is a broad term and is given its usual and customary meaning to those skilled in the art (and is not limited to any special or customized meaning), and refers without limitation to a salt of a compound that does not cause significant irritation to the organism to which it is administered and does not abrogate the biological activity and properties of the compound. In some embodiments, the salt is an acid addition salt of the compound. Pharmaceutical salts can be obtained by reacting a compound with inorganic acids such as hydrohalic acid (e.g., hydrochloric acid or hydrobromic acid), sulfuric acid, nitric acid and phosphoric acid. Pharmaceutical salts can also be obtained by reacting the compounds with organic acids such as aliphatic or aromatic carboxylic or sulfonic acids, for example, formic acid, acetic acid (AcOH), propionic acid, glycolic acid, pyruvic acid, malonic acid, maleic acid, fumaric acid, trifluoroacetic acid (TFA), benzoic acid, cinnamic acid, mandelic acid, succinic acid, lactic acid, malic acid, tartaric acid, citric acid, ascorbic acid, nicotinic acid, methanesulfonic acid, ethanesulfonic acid, p-toluensulfonic acid, salicylic acid, stearic acid, muconic acid, butyric acid, phenylacetic acid, phenylbutyric acid, valproic acid, 1,2-ethanedisulfonic acid, 2-hydroxyethanesulfonic acid, benzenesulfonic acid, 2-naphthalenesulfonic acid, or naphthalenesulfonic acid. Pharmaceutical salts are formed by reacting a compound with a base to produce ammonium salts, alkali metal salts (such as lithium, sodium or potassium salts), alkaline earth metal salts (such as calcium, magnesium or aluminum salts), dicyclohexylamine, N-methyl-D-glucamine, tris(hydroxymethyl)methylamine, (C 1 ~C 7They may also be obtained by forming salts such as salts with organic bases, such as alkylamines, cyclohexylamine, dicyclohexylamine, triethanolamine, ethylenediamine, ethanolamine, diethanolamine, triethanolamine, tromethamine, and salts with amino acids, such as arginine and lysine; or salts with inorganic bases, such as aluminum hydroxide, calcium hydroxide, potassium hydroxide, sodium carbonate, sodium hydroxide, etc. In some embodiments, the compounds described herein may be in the form of a trifluoroacetate salt.

[0083] As used herein, a "nucleotide" comprises a nitrogen-containing heterocyclic base, a sugar, and one or more phosphate groups. They are the monomeric units of nucleic acid sequences. In RNA, the sugar is ribose, and in DNA, it is deoxyribose, i.e., a sugar without the hydroxyl group present in ribose. The nitrogen-containing heterocyclic base can be a purine or pyrimidine base. Purine bases include adenine (A) and guanine (G), as well as modified derivatives or analogs thereof, such as deazapurines or 7-deazapurines. Pyrimidine bases include cytosine (C), thymine (T), and uracil (U), as well as modified derivatives or analogs thereof. The C-1 atom of deoxyribose is attached to the N-1 of a pyrimidine or the N-9 of a purine.

[0084] As used herein, a "nucleoside" is structurally similar to a nucleotide, but without the phosphate moiety. An example of a nucleoside analog is one in which a label is linked to the base and there is no phosphate group attached to the sugar molecule. The term "nucleoside" is used herein with its normal meaning as understood by those skilled in the art. Examples include, but are not limited to, ribonucleosides that contain a ribose moiety, and deoxyribonucleosides that contain a deoxyribose moiety. Modified pentose moieties are those in which an oxygen atom is replaced by a carbon and / or a carbon is replaced by a sulfur or oxygen atom. A "nucleoside" is a monomer that can have a substituted base and / or sugar moiety. Additionally, nucleosides can be incorporated into larger DNA and / or RNA polymers and oligomers.

[0085] A "nucleotide residue" is a nucleotide, which is a single residue of a polynucleotide. Once incorporated into a polynucleotide, a nucleotide monomer becomes a nucleotide residue. The terminal nucleotide residue of a polynucleotide may be indirectly attached to a solid support through the other end of the polynucleotide, for example, through a linker (the other end of the polynucleotide is a part of the polynucleotide), or the terminal nucleotide residue may be directly attached to a solid support, for example, when it is the first nucleotide residue of an oligonucleotide chain, as may be done, for example, in the synthesis of an array.

[0086] The term "purine base" is used herein in its ordinary sense as understood by those skilled in the art, and includes its tautomers. Similarly, the term "pyrimidine base" is used herein in its ordinary sense as understood by those skilled in the art, and includes its tautomers. A non-limiting list of optionally substituted purine bases includes purine, deazapurine, 7-deazapurine, adenine, 7-deazaadenine, guanine, 7-deazaguanine, hypoxanthine, xanthine, alloxanthine, 7-alkylguanine (e.g., 7-methylguanine), theobromine, caffeine, uric acid, and isoguanine. Examples of pyrimidine bases include, but are not limited to, cytosine, thymine, uracil, 5,6-dihydrouracil, and 5-alkylcytosine (e.g., 5-methylcytosine).

[0087] As used herein, "derivative" or "analog" refers to synthetic nucleoside or nucleotide derivatives with modified base moieties and / or modified sugar moieties. Such derivatives and analogs are discussed, for example, in Scheit, Nucleotide Analogs (John Wiley & Son, 1980) and Uhlman et al., Chemical Reviews 90:543-584, 1990. Nucleotide analogs can also include modified phosphodiester linkages, including phosphorothioate, phosphorodithioate, alkyl-phosphonate, phosphoranilidate, phosphoramidite and phosphoramidite linkages. As used herein, "derivative" and "analog" may be used interchangeably and are encompassed by the terms "nucleotide" and "nucleoside" as defined herein.

[0088] As used herein, the term "phosphate" is used in its ordinary sense as understood by one of ordinary skill in the art and includes its protonated forms (e.g., [ka] and [ka] As used herein, the terms "monophosphate," "diphosphate," and "triphosphate" are used in their ordinary sense, as understood by those of skill in the art, and include protonated forms. Additionally, in oligonucleotides or polynucleotides described herein that contain one or more phosphodiester linkages, each phosphodiester linkage may be present in both protonated forms, e.g., [ka] where X is O or S, and the unprotonated form [ka] or salt forms.

[0089] 2'-protected nucleosides of formula (I) Some embodiments include a compound of formula (I) or a pharma- ceutically acceptable salt thereof, as described herein: [ka] (I) or a pharma- ceutically acceptable salt thereof.

[0090] In some embodiments of the compounds of Formula (I), R 1 is hydrogen or a hydroxy protecting group. In some embodiments, R 1 is hydrogen. In other embodiments, R 1 is a trityl-type hydroxy protection selected from (4-methoxyphenyl)diphenylmethyl, bis(4-methoxyphenyl)phenylmethyl, tris(4-methoxyphenyl)methyl, 9-phenylxanthen-9-yl, and 9-(4-methoxyphenyl)xanthen-9-yl. In some specific embodiments, R 1In another embodiment, -OR is bis(4-methoxyphenyl)phenylmethyl. 1 is a monophosphate, diphosphate or triphosphate.

[0091] In some embodiments of the compounds of Formula (I), R 2 is hydrogen, a hydroxy protecting group, -C(=O)CH 2 CH 2 C(=O)R 3 OR-P(OR 4 )NR 5 R 6 In some embodiments, R 2 is hydrogen. In other embodiments, R 2 is a hydroxy protecting group. In some embodiments, R 2 is -C(=O)CH 2 CH 2 C(=O)R 3 and R 3 -OH, -OR 7 or -NR 8 R 9 In some embodiments, R 7 is unsubstituted C 1 ~C 6 Alkyl, substituted C 1 ~C 6 is an alkyl or hydroxy protecting group. In some embodiments, R 8 and R 9 each independently represents H, optionally substituted C, 1~6 is an alkyl or amino protecting group. 2 is -C(=O)CH 2 CH 2 C(=O)OH. In another embodiment, R 2 -P(OR 4 )NR 5 R 6 and R 4 , R 5 and R 6 are each independently H, unsubstituted C 1~6 Alkyl or substituted C 1~6 In some embodiments, R 2-P(OR 4 )NR 5 R 6 and R 4 is a substitution C 1~6 is alkyl, R 5 and R 6 are each independently an unsubstituted C 1 ~C 6 In another embodiment, R 4 is an unsubstituted C such as methyl, ethyl, isopropyl, etc. 1~6 In one embodiment, R 2 teeth, [ka] It is.

[0092] In some other embodiments of the compounds of formula (I), R 1 and R 2 are joined together to form a 6-10 membered heterocyclic ring. 1 and R 2 are joined together to form a seven-membered heterocyclic ring containing an oxygen atom and a silicon atom, for example, the compound has the formula (Ia): [ka] (Ia) or a pharma- ceutically acceptable salt thereof. A , R B , R C and R D are each independently H, unsubstituted C 1 ~C 6 Alkyl or substituted C 1 ~C 6 In some specific embodiments, R A , R B , R C and R D are each isopropyl.

[0093] In some embodiments of the compounds of Formula (I) or (Ia), R Hetis an optionally substituted 5-10 membered heteroaryl containing 1-4 heteroatoms selected from the group consisting of O, N, and S. In some further embodiments, R Het is selected from the group consisting of pyridinyl, pyrimidinyl, furanyl, pyrrolyl, thienyl, thiazolyl, isothiazolyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, benzofuranyl, benzimidazolyl, benzopyrazolyl, benzothiazolyl, benzoxazolyl, indolyl and quinolinyl, each optionally substituted by one, two or three substituents Q, each of which is halo, cyano, hydroxy, amino, C 1 ~C 6 Alkyl, C 1 ~C 6 Haloalkyl, Hydroxy (C 1 ~C 6 Alkyl), Amino (C 1 ~C 6 Alkyl), (C 1 ~C 6 Alkyl)amino, C 1 ~C 6 Alkoxy, C 1 ~C 6 Haloalkoxy, (C 1 ~C 6 Alkoxy)C 1 ~C 6 Alkyl and -O(C 1 ~C 6 Alkoxy)C 1 ~C 6 In some embodiments, R Het is 4-pyridinyl optionally substituted with one, two or three substituents Q. In some embodiments, R Het is 4-pyridinyl optionally substituted with one, two or three substituents Q, each of which is -F, -Cl, -Br, -CH 3 , -CH 2 CH 3 , -CF 3 , -CH 3 , -OCH 3 and -OCH 2 CH3 are independently selected from the group consisting of:

[0094] In some other embodiments of the compounds of Formula (I) or (Ia), R Het is an optionally substituted 5-10 membered heterocyclyl containing 1-4 heteroatoms selected from the group consisting of O, N and S. In a further embodiment, R Het is selected from the group consisting of tetrahydrofuranyl, tetrahydropyranyl, pyrrolidinyl, piperidinyl, piperazinyl and morpholinyl, each of which is optionally substituted with one, two or three substituents Q, each of which is halo, cyano, hydroxy, amino, C 1 ~C 6 Alkyl, C 1 ~C 6 Haloalkyl, Hydroxy (C 1 ~C 6 Alkyl), Amino (C 1 ~C 6 Alkyl), (C 1 ~C 6 Alkyl)amino, C 1 ~C 6 Alkoxy, C 1 ~C 6 Haloalkoxy, (C 1 ~C 6 Alkoxy)C 1 ~C 6 Alkyl and -O(C 1 ~C 6 Alkoxy)C 1 ~C 6 In some embodiments, each Q is independently selected from the group consisting of -F, -Cl, -Br, -CH 3 , -CH 2 CH 3 , -CF 3 , -CH 3 , -OCH 3 and -OCH 2 CH 3 are independently selected from the group consisting of:

[0095] In some embodiments of the compounds of formula (I) or (Ia), B is a natural nucleobase. In other embodiments, B is a modified natural nucleobase. In yet other embodiments, B is a non-natural nucleobase. In some embodiments, B is [ka] In another embodiment, B is [ka] In another embodiment, B is [ka] In yet another embodiment, B is [ka] In yet another embodiment, B is [ka] In some embodiments, B is [ka] In some embodiments, R x is hydrogen, C 1 ~C 6 alkyl (such as methyl, ethyl, isopropyl, n-butyl, t-butyl, etc.) or an amino protecting group. In one embodiment, R x is methyl. In another embodiment, -NHR x There is no hydrogen in R x is a divalent amino protecting group. In some embodiments, R x is -C(=O)C 1~6 For example, in some embodiments, R x is -C(=O)CH 3 (Ac), -C(=O)CH 2 CH 3 or -C(=O)CH(CH 3 ) 2(iBu). In another embodiment, R x is -C(=O)-phenyl. In some other embodiments, -NHR x There is no hydrogen in R x The direct bond of R to the nitrogen atom forms an amino protecting group, such as an amidine-type protecting group or a phthaloyl-type protecting group. x is N,N,-dimethylformamidine [ka] In some other embodiments, R x teeth, [ka] It is.

[0096] Additional non-limiting examples of compounds of formula (I) include: [ka] [ka] and salts thereof, R 2 H, [ka] -C(=O)CH 2 CH 2 C(=O)OH or -C(=O)CH 2 CH 2 C(=O)NH 2 and [ka] are each optionally substituted with one substituent Q, where Q is -F, -Cl, -Br, -CH 3 , -CH 2 CH 3 , -CF 3 , -CH 3 , -OCH 3 and -OCH 2 CH3 and B is a natural nucleobase, a modified natural nucleobase, or a non-natural nucleobase, as described herein. In some embodiments, R 2 teeth, [ka] In some further embodiments, B is [ka] In yet a further embodiment, R x -C(=O)Ph(Bz), -C(=O)CH 3 (Ac) or -C(=O)CH(CH 3 ) 2 (iBu).

[0097] Additional non-limiting examples of compounds of formula (I) include the following: [ka] [ka] Contains R x -C(=O)Ph(Bz), -C(=O)CH 3 (Ac) or -C(=O)CH(CH 3 ) 2 (iBu), and R 2 teeth, [ka] or -C(=O)CH 2 CH 2 C(=O)OH.

[0098] In an embodiment of any of the compounds of formula (I) or (Ia) described herein, the compound is 2 For example, R 2 But -C(=O)CH 2 CH 2C(=O)OH, the compound has the moiety: [ka] where W is O or NH, the dashed line indicates the connection to the solid support, optionally via an additional linker, and the wavy line indicates the R 2 The solid support may be covalently attached to the solid support via a bond (referring to the point of attachment of the oxygen atom covalently bonded to the remainder of the compound). In some embodiments, the solid support is a controlled pore glass (CPG) solid support.

[0099] Removal of 2' protecting group Some embodiments of the present disclosure include: Structure of formula (II): [ka] The present invention relates to a method for deprotecting an oligonucleotide or polynucleotide comprising at least one 2' protected nucleotide residue, comprising contacting the oligonucleotide or polynucleotide with a composition comprising an amine (e.g., a primary amine) or ammonia to deprotect the 2' protected nucleotide residue.

[0100] In some embodiments of the deprotection method described herein, the 2' protecting group of the nucleotide residue can be removed in the presence of one or more amines in a solvent, such as a solvent containing alcohol. In some such embodiments, the amine can be a primary amine, a secondary amine, or a tertiary amine, or a combination thereof. In one embodiment, the 2' protecting group can be removed by treatment with ammonia in methanol. In other embodiments, the 2' protecting group can be removed by treatment with n-butylamine in methanol.

[0101] In some embodiments of the deprotection methods described herein, R 4 is H. In other embodiments, R 4 is unsubstituted C1 ~C 6 Alkyl or substituted C 1 ~C 6 In one such embodiment, R 4 is -CH 2 CH 2 In another embodiment, R 4 is methyl. In another embodiment, R 4 is ethyl. [ka] but, [ka] This compound also has the unprotonated form [ka] In some embodiments, X is O or S. In some further embodiments, X is O. In some embodiments, B is a natural nucleobase. In other embodiments, B is a modified natural nucleobase. In yet other embodiments, B is a non-natural nucleobase. In some embodiments, B is [ka] In another embodiment, B is [ka] In another embodiment, B is [ka] In yet another embodiment, B is [ka] In yet another embodiment, B is [ka] In some embodiments, B is [ka] In some embodiments, R x is hydrogen, C 1 ~C 6 alkyl (such as methyl, ethyl, isopropyl, n-butyl, t-butyl, etc.) or an amino protecting group. In one embodiment, R x is methyl. In another embodiment, -NHR x There is no hydrogen in R x is a divalent amino protecting group. In some embodiments, R x is -C(=O)C 1~6 For example, in some embodiments, R x is -C(=O)CH 3 (Ac), -C(=O)CH 2 CH 3 or -C(=O)CH(CH 3 ) 2 (iBu). In another embodiment, R x is -C(=O)phenyl. In some other embodiments, -NHR x There is no hydrogen in R x The direct bond of R to the nitrogen atom forms an amino protecting group, such as an amidine-type protecting group or a phthaloyl-type protecting group. x is N,N,-dimethylformamidine [ka] In some other embodiments, R x teeth, [ka] It is.

[0102] In some embodiments of the deprotection methods described herein, R Het is an optionally substituted 5-10 membered heteroaryl or an optionally substituted 5-10 membered heterocyclyl. In a further embodiment, RHet is an optionally substituted 5-10 membered heteroaryl containing 1-4 heteroatoms selected from the group consisting of O, N, and S. In some such embodiments, R Het is selected from the group consisting of pyridinyl, pyrimidinyl, furanyl, pyrrolyl, thienyl, thiazolyl, isothiazolyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, benzofuranyl, benzimidazolyl, benzopyrazolyl, benzothiazolyl, benzoxazolyl, indolyl and quinolinyl, each optionally substituted by one, two or three substituents Q, each of which is halo, cyano, hydroxy, amino, C 1 ~C 6 Alkyl, C 1 ~C 6 Haloalkyl, Hydroxy (C 1 ~C 6 Alkyl), Amino (C 1 ~C 6 Alkyl), (C 1 ~C 6 Alkyl)amino, C 1 ~C 6 Alkoxy, C 1 ~C 6 Haloalkoxy, (C 1 ~C 6 Alkoxy)C 1 ~C 6 Alkyl and -O(C 1 ~C 6 Alkoxy)C 1 ~C 6 In some embodiments, R Het is 4-pyridinyl optionally substituted with one, two or three substituents Q. In some embodiments, R Het is 4-pyridinyl optionally substituted with one, two or three substituents Q, each of which is -F, -Cl, -Br, -CH 3 , -CH 2 CH 3 , -CF 3 , -CH 3 , -OCH 3 and -OCH2 CH 3 are independently selected from the group consisting of:

[0103] In some other embodiments of the deprotection methods described herein, optionally substituted 5-10 membered heterocyclyl containing 1-4 heteroatoms selected from the group consisting of O, N and S. In further embodiments, R Het is selected from the group consisting of tetrahydrofuranyl, tetrahydropyranyl, pyrrolidinyl, piperidinyl, piperazinyl and morpholinyl, each of which is optionally substituted with one, two or three substituents Q, each of which is halo, cyano, hydroxy, amino, C 1 ~C 6 Alkyl, C 1 ~C 6 Haloalkyl, Hydroxy (C 1 ~C 6 Alkyl), Amino (C 1 ~C 6 Alkyl), (C 1 ~C 6 Alkyl)amino, C 1 ~C 6 Alkoxy, C 1 ~C 6 Haloalkoxy, (C 1 ~C 6 Alkoxy)C 1 ~C 6 Alkyl and -O(C 1 ~C 6 Alkoxy)C 1 ~C 6 In some embodiments, each Q is independently selected from the group consisting of -F, -Cl, -Br, -CH 3 , -CH 2 CH 3 , -CF 3 , -CH 3 , -OCH 3 and -OCH 2 CH 3 are independently selected from the group consisting of:

[0104] In some further embodiments of the deprotection method, the 2' nucleotide residue is [ka] R 4 is H, methyl, ethyl or -CH 2 CH 2 CN, [ka] are each optionally substituted with 1 to 3 substituents Q, each of which is -F, -Cl, -Br, -CH 3 , -CH 2 CH 3 , -CF 3 , -CH 3 , -OCH 3 and -OCH 2 CH 3 and B is as described. In a further embodiment, X is O. In a further embodiment, B is [ka] In a further embodiment, R x -C(=O)Ph(Bz), -C(=O)CH 3 (Ac) or -C(=O)CH(CH 3 ) 2 (iBu).

[0105] In some further embodiments of the deprotection method, the oligonucleotide or polynucleotide is bound to a solid support.

[0106] Some additional embodiments of the present disclosure relate to oligonucleotides or polynucleotides prepared by the 2' deprotection methods described herein.

[0107] Additional embodiments of the present disclosure include phosphate protecting groups, nucleobase protecting groups (e.g., R 4and a method for deprotecting a nucleotide residue comprising a 2'-protecting group having the structure of formula (II) as described herein. In certain embodiments, the method comprises the steps of: (a) contacting an oligonucleotide or polynucleotide with a first composition comprising a phosphate deprotection reagent under conditions sufficient to remove a phosphate protecting group to produce a first deprotected polynucleotide; (b) contacting the first deprotected polynucleotide with a second composition comprising a 2' deprotection reagent described herein under conditions sufficient to remove the 2' protecting group to produce a second deprotected polynucleotide; and (c) contacting the second deprotected polynucleotide with a third composition comprising a diamine under conditions sufficient to remove the nucleobase protecting groups to produce a fully deprotected polynucleotide. Includes.

[0108] In some embodiments, any two or three of steps (a)-(c) may be carried out under the same conditions or simultaneously. In further embodiments, the method is a one-pot reaction.

[0109] In further embodiments, the methods described herein produce cleaved polynucleotides, where the cleaved polynucleotides are retained on a solid support. The method may further include washing the solid support and the cleaved polynucleotides, and eluting the cleaved polynucleotides from the solid support.

[0110] In certain embodiments, the cleaved polynucleotide is retained on a solid support, allowing the cleaved polynucleotide to be easily separated from the composition and the deprotected protecting group product, for example, by one or more washing steps. The composition can also be removed from the cleaved polynucleotide by drying, evaporation, vacuum steps, etc.

[0111] 2'-protected nucleoside phosphoramidites in RNA synthesis Some embodiments of the present application relate to a method of preparing a synthetic oligonucleotide, comprising reacting a compound of formula (I) described herein with an oligonucleotide. In some embodiments, the oligonucleotide comprises 1-100 bases in length, 5-50 bases in length, or 10-30 bases in length. In further embodiments, the reaction is carried out on a solid support. In particular, the compound of formula (I) comprises a 3' phosphoramidite group (i.e., R 2 -P(OR 4 )NR 5 R 6 In a further embodiment, R 2 teeth, [ka] For example, a compound of formula (I) described herein may be reacted with an unprotected hydroxy group of an oligonucleotide or polynucleotide (e.g., the 5' terminal hydroxy of an oligonucleotide or polynucleotide).

[0112] Additional embodiments of the present disclosure relate to oligonucleotides or polynucleotides prepared by the synthetic processes described herein.

[0113] In particular, certain embodiments include Structure of formula (II): [ka] The present invention relates to a solid support-bound oligonucleotide or polynucleotide comprising at least one 2'-protected ribonucleotide residue comprising:

[0114] In some embodiments of the surface-bound oligonucleotides or polynucleotides described herein, R 4 is unsubstituted C 1 ~C6 Alkyl or substituted C 1 ~C 6 In one such embodiment, R 4 is -CH 2 CH 2 In another embodiment, R 4 is methyl or ethyl. In another embodiment, R 4 is H. The moiety of formula (II) [ka] but, [ka] This compound also has the unprotonated form [ka] In some embodiments, X is O or S. In some further embodiments, X is O. In some embodiments, B is a natural nucleobase. In other embodiments, B is a modified natural nucleobase. In yet other embodiments, B is a non-natural nucleobase. In some embodiments, B is [ka] In another embodiment, B is [ka] In another embodiment, B is [ka] In yet another embodiment, B is [ka] In yet another embodiment, B is [ka] In some embodiments, B is [ka] In some embodiments, R x is hydrogen, C 1 ~C 6 alkyl (such as methyl, ethyl, isopropyl, n-butyl, t-butyl, etc.) or an amino protecting group. In one embodiment, R x is methyl. In another embodiment, -NHR x There is no hydrogen in R x is a divalent amino protecting group. In some embodiments, R x is -C(=O)C 1~6 For example, in some embodiments, R x is -C(=O)CH 3 (Ac), -C(=O)CH 2 CH 3 or -C(=O)CH(CH 3 ) 2 (iBu). In another embodiment, R x is -C(=O)-phenyl. In some other embodiments, -NHR x There is no hydrogen in R x The direct bond of R to the nitrogen atom forms an amino protecting group, such as an amidine-type protecting group or a phthaloyl-type protecting group. x is N,N,-dimethylformamidine [ka] In some other embodiments, R x teeth, [ka] It is.

[0115] In some embodiments of the surface-bound oligonucleotides or polynucleotides described herein, R Het is an optionally substituted 5-10 membered heteroaryl or an optionally substituted 5-10 membered heterocyclyl. For example, R Hetis an optionally substituted 5-10 membered heteroaryl containing 1-4 heteroatoms selected from the group consisting of O, N, and S. In some further embodiments, R Het is selected from the group consisting of pyridinyl, pyrimidinyl, furanyl, pyrrolyl, thienyl, thiazolyl, isothiazolyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, benzofuranyl, benzimidazolyl, benzopyrazolyl, benzothiazolyl, benzoxazolyl, indolyl and quinolinyl, each optionally substituted by one, two or three substituents Q, each of which is halo, cyano, hydroxy, amino, C 1 ~C 6 Alkyl, C 1 ~C 6 Haloalkyl, Hydroxy (C 1 ~C 6 Alkyl), Amino (C 1 ~C 6 Alkyl), (C 1 ~C 6 Alkyl)amino, C 1 ~C 6 Alkoxy, C 1 ~C 6 Haloalkoxy, (C 1 ~C 6 Alkoxy)C 1 ~C 6 Alkyl and -O(C 1 ~C 6 Alkoxy)C 1 ~C 6 In some embodiments, R Het is 4-pyridinyl optionally substituted with one, two or three substituents Q. In some embodiments, R Het is 4-pyridinyl optionally substituted with one, two or three substituents Q, each of which is -F, -Cl, -Br, -CH 3 , -CH 2 CH 3 , -CF 3 , -CH 3 , -OCH 3 and -OCH 2 CH3 are independently selected from the group consisting of:

[0116] In other embodiments of the portion of the surface-bound oligonucleotides or polynucleotides described herein, R Het is an optionally substituted 5-10 membered heterocyclyl containing 1-4 heteroatoms selected from the group consisting of O, N, and S. In some such embodiments, R Het is selected from the group consisting of tetrahydrofuranyl, tetrahydropyranyl, pyrrolidinyl, piperidinyl, piperazinyl and morpholinyl, each of which is optionally substituted with one, two or three substituents Q, each of which is halo, cyano, hydroxy, amino, C 1 ~C 6 Alkyl, C 1 ~C 6 Haloalkyl, Hydroxy (C 1 ~C 6 Alkyl), Amino (C 1 ~C 6 Alkyl), (C 1 ~C 6 Alkyl)amino, C 1 ~C 6 Alkoxy, C 1 ~C 6 Haloalkoxy, (C 1 ~C 6 Alkoxy)C 1 ~C 6 Alkyl and -O(C 1 ~C 6 Alkoxy)C 1 ~C 6 In some embodiments, each Q is independently selected from the group consisting of -F, -Cl, -Br, -CH 3 , -CH 2 CH 3 , -CF 3 , -CH 3 , -OCH 3 and -OCH 2 CH 3 are independently selected from the group consisting of:

[0117] In further embodiments of the surface bound oligonucleotides or polynucleotide portions described herein, the 2' nucleotide residue is [ka] [ka] is selected from the group consisting of [ka] are each optionally substituted with 1 to 3 substituents Q, each of which is -F, -Cl, -Br, -CH 3 , -CH 2 CH 3 , -CF 3 , -CH 3 , -OCH 3 and -OCH 2 CH 3 and B is as described. In further embodiments, X is O. In some embodiments, B is [ka] In some further embodiments, R x -C(=O)Ph(Bz), -C(=O)CH 3 (Ac) or -C(=O)CH(CH 3 ) 2 (iBu).

[0118] A general description of oligo synthesis is detailed below.

[0119] Step 1: De-blocking (detritylation) The DMTr group is removed with a solution of an acid such as 2% trichloroacetic acid (TCA) or 3% dichloroacetic acid (DCA) in an inert solvent (dichloromethane or toluene). The orange DMTr cation formed is washed away. This step results in a solid support-bound oligonucleotide precursor with a free 5'-terminal hydroxy group.

[0120] Step 2: Coupling A 0.02-0.2 M solution of a nucleoside phosphoramidite (or a mixture of several phosphoramidites) in acetonitrile is activated by a 0.2-0.7 M solution of the acidic azole catalyst 1H-tetrazole, 5-ethylthio-1H-tetrazole, 2-benzylthiotetrazole, 4,5-dicyanoimidazole or some similar compound. This mixing is usually very short and is performed in the fluid lines of an oligonucleotide synthesizer (see below) while delivering the components to a reactor containing a solid support. A 1.5-20-fold excess of the activated phosphoramidite over the support-bound material is then contacted with the starting solid support (first coupling), or with a support-bound oligonucleotide precursor (after coupling), where the 5'-hydroxy group of the oligonucleotide precursor reacts with the activated phosphoramidite moiety of the incoming nucleoside phosphoramidite to form a phosphite triester linkage. The reaction is also very sensitive to the presence of water, especially when dilute solutions of the phosphoramidites are used, and is generally carried out in anhydrous acetonitrile. Upon completion of the coupling, any unbound reagents and by-products are removed by washing.

[0121] Step 3: Capping The capping step, performed by treatment of the solid support-bound material with a mixture of acetic anhydride and 1-methylimidazole (or less frequently, DMAP) as a catalyst, serves two purposes in the phosphoramidite method. After completion of the coupling reaction, a small percentage of the solid support-bound 5'-OH groups (0.1-1%) remain unreacted and must be permanently blocked from further chain extension to prevent the formation of oligonucleotides lacking an internal base, commonly referred to as (n-1) shortmers. The unreacted 5'-hydroxy groups are, to a large extent, acetylated by the capping mixture.

[0122] Step 4: Oxidation The newly formed three-coordinate phosphite triester linkage is not naturally occurring and has limited stability under the conditions of oligonucleotide synthesis. Treatment of the support-bound material with iodine and water in the presence of a weak base (pyridine, lutidine, or collidine) oxidizes the phosphite triester to a four-coordinate phosphate triester, which is the protected precursor of the naturally occurring phosphodiester internucleoside linkage. Oxidation may be performed under anhydrous conditions using tert-butyl hydroperoxide or (1S)-(+)-(10-camphorsulfonyl)-oxaziridine (CSO). The oxidation step can be replaced by a sulfurization step to obtain oligonucleotide phosphorothioates. In the latter case, the sulfurization step is best performed before capping.

[0123] In solid phase synthesis, the oligonucleotides to be assembled are covalently attached to a solid support material through their 3'-terminal hydroxy groups and remain attached to the solid support material throughout the entire course of chain assembly. The solid support is placed into a column whose dimensions depend on the scale of the synthesis and can vary between 0.05 mL to several liters. At the end of chain assembly, the oligonucleotides are released from the solid support and eluted from the column or well. The two most commonly used solid phase materials are controlled pore glass (CPG) and macroporous polystyrene (MPPS).

[0124] In contrast to organic solid phase synthesis and peptide synthesis, the synthesis of oligonucleotides is best carried out on non-swelling or low-swelling solid supports. The two most commonly used solid phase materials are controlled pore glass (CPG) and macroporous polystyrene (MPPS).

[0125] CPGs are generally defined by their pore size. In oligonucleotide chemistry, pore sizes of 500, 1000, 1500, 2000 and 3000 Å are used to allow the preparation of oligonucleotides of about 50, 80, 100, 150 and 200 mers, respectively. To create native CPGs suitable for further processing, the surface of this material is treated with (3-aminopropyl)triethoxysilane to obtain aminopropyl CPGs. The aminopropyl arms can be further extended to give long chain aminoalkyl (LCAA) CPGs. The amino groups are then used as anchoring points for linkers suitable for oligonucleotide synthesis.

[0126] The MPPS suitable for oligonucleotide synthesis is a low swelling, highly crosslinked polystyrene obtained by polymerization of divinylbenzene, styrene and 4-chloromethylstyrene in the presence of a porogeneous agent. The resulting macroporous chloromethyl MPPS is converted to aminomethyl MPPS. EXAMPLES

[0127] Certain aspects of the embodiments discussed above are disclosed in further detail in the following examples, which are not intended to limit the scope of the disclosure in any way. Those skilled in the art will recognize that numerous other embodiments also fall within the scope of the compositions, kits and methods of the present application, as described above and in the claims herein. Example 1 Preparation of 2'-O-protected phosphoramidites, succinates, and conjugation to solid supports [ka]

[0128] Step 1: Compound 1 was synthesized according to the literature (J. Am. Chem. Soc. 2009, 131, 8496-8502). Under argon, uridine (1.0 g, 4.1 mmol) was dissolved in pyridine (10.0 mL), and then 1,3-dichloro-1,1,3,3-tetraisopropyldisiloxane (TIPDSiCl 2 ) (1.37 mL, 4.3 mmol) was added. The reaction mixture was stirred at room temperature for 2.5 hours and diluted with dichloromethane (DCM) (10 mL). Brine (10 mL) was then added to the reaction and the organic phase was separated. The aqueous phase was extracted twice with dichloromethane (10 mL) and the combined organic phase was washed with Na 2 SO 4 After drying at 4° C., filtration and concentration to dryness, a white foam (crude: 2.35 g) was obtained, which was used without further purification.

[0129] Step 2: Compound 2 was synthesized according to the literature (J. Am. Chem. Soc. 2009,131, 8496-8502). Compound 1 (4.1 mmol) from step 1 was dissolved in dimethyl sulfoxide (DMSO) (7.9 mL), and then acetic acid (14 mL) and acetic anhydride (13.7 mL) were added. The reaction mixture was heated to 50° C. overnight and cooled to room temperature. The solution was poured into a 2 L Erlenmeyer flask with vigorous stirring and added with K 2 CO 3 Solution of (H 2 A 100 mL solution of 56 g in 500 mL of HO was added. The white precipitate was filtered, dissolved in dichloromethane, dried over magnesium sulfate, filtered and concentrated to dryness. The crude material was purified by flash column chromatography (0-50% ethyl acetate in dichloromethane) to give a pale yellow foam (1.05 g, 46.9% yield). MS: Found: [MH] = 545.5; Calculated: [MH] = 545.2.

[0130] Step 3: Under a dry argon atmosphere, compound 2 from step 2 (1.05 g, 1.92 mmol) was dissolved in 38 mL of dichloromethane and cooled to -10°C. Sulfuryl chloride (0.23 mL) was then added dropwise over 4 minutes. The reaction was stirred at room temperature for 1 hour. The solvent was then removed under reduced pressure to give a yellow foam which was subsequently dissolved in 9.6 mL of dichloromethane. The sodium salt of isonicotinic acid (4.8 mmol) was then added to the stirred solution followed by 15-crown-5 (1.1 mmol). The reaction mixture was stirred for 1 hour and then washed with 50 mL of H 2 The crude material was then purified by column chromatography (0-8% methanol in dichloromethane) to give compound 3 as a white foamy solid in 45.2% yield. MS: Found: [M+H]=622.7; Calcd: [M+H]=622.3 [ka]

[0131] Compound 2 (0.91 g, 1.66 mmol) was dissolved in 33 mL of dichloromethane (DCM) under dry argon and cooled to -10°C. Sulfuryl chloride (0.20 mL, 2.50 mmol) was then added dropwise over 4 minutes. The reaction was stirred at room temperature for 2 hours. The solvent was then removed under reduced pressure to give a yellow foam. This material was then dissolved in 16 mL of tetrahydrofuran (THF) and to the stirred solution was added the sodium salt of 4-quinoline carboxylic acid (0.72 g, 4.15 mmol) followed by 15-crown-5 (42 μL, 0.21 mmol). The reaction mixture was stirred at room temperature overnight and 50 mL of saturated NaHCO 3The mixture was quenched with 50 mL of ethyl acetate. The solution was then transferred to a separatory funnel and the organic phase was separated. The aqueous layer was then extracted with ethyl acetate (3×50 mL) and the organic phases were combined and dried over magnesium sulfate. After filtration, the solvent was removed under reduced pressure to give a yellowish foam. The crude material was then purified by column chromatography (0-90% ethyl acetate in hexanes) to give compound 4 as a white solid (0.21 g). MS: Found: [M+H]=672.7; Calculated: [M+H]=672.3. [ka]

[0132] Removal of the silyl protecting group: Compound 4 (0.21 g, 0.312 mmol) was dissolved in tetrahydrofuran (THF, 4.0 mL) and pyridine hydrofluoride (70% HF, 0.10 mL, 1.11 mmol) was added. The reaction was stirred at room temperature overnight. The reaction mixture was diluted with saturated NaHCO 3 (20 mL) was added and the solution was then extracted three times with ethyl acetate (20 mL). The organic phase was concentrated to dryness under vacuum. The crude material was then purified by column chromatography (0-10% MeOH in DCM) to give compound 5 as a white solid (60 mg, 44.7% yield). MS: Found [MH] = 428.4; Calculated: [MH] = 428.1. [ka]

[0133] Compound 5 (95 mg, 0.221 mmol) was dissolved in pyridine (1.5 mL) and then DMTrCl (85 mg, 0.252 mmol) was added. The reaction mixture was stirred at room temperature overnight. The reaction was quenched with 5% NaHCO3 solution and extracted with DCM (3 x 5 mL). The combined organic phase was dried over magnesium sulfate, filtered and concentrated to dryness. The crude material was then purified by column chromatography (0-10% MeOH in DCM) to give compound 6 as a white solid (24 mg). MS: Found [M+H] = 732.5; Calculated: [M+H] = 732.3. [ka]

[0134] Compound 6 (24 mg, 0.0327 mmol) was dissolved in anhydrous DCM under argon. 2-Cyanoethyl N,N,N',N'-tetraisopropylphosphordiamidite (18.5 μL) and diisopropylammonium tetrazole (1.4 mg) were added. The reaction mixture was stirred at room temperature for 2 h and saturated NaHCO3 (2 mL) was added. DCM (4 mL) was added and transferred to a separatory funnel. The aqueous phase was separated and extracted twice with DCM (2 mL). The combined organic phase was diluted with Na 2 SO 4 The mixture was dried at 40° C., filtered and concentrated to dryness to give compound 7. MS: Found [M+H]=932.9; Calculated: [M+H]=932.4. [ka]

[0135] Compound 8. Step 1: In a 50 mL RB flask, compound 6 (111 mg, 0.152 mmol) was dissolved in 10 mL DCM. Succinic anhydride (22.8 mg, 0.228 mmol), TEA (30.7 mg, 0.307 mmol) were added. The reaction mixture was stirred at room temperature for 2 h. The reaction was complete by TLC. The mixture was then poured into saturated NaHCO3 (10 mL), DCM (20 mL) was added, the organic layer was separated, washed with water, brine, and NaHCO3 (10 mL).2 SO 4 The mixture was dried at rt. After filtration, the organic layer was concentrated to dryness under vacuum. The crude product was purified by column purification using DCM / MeOH (0%-10% MeOH). The pure fractions were collected and concentrated to dryness under vacuum to give the corresponding succinate (15 mg). MS: Found: [MH]=830.5; Calculated: [MH]=830.3.

[0136] Step 2: In a 50 mL RB flask, the succinate from above (15 mg, 0.018 mmol) was dissolved in MeCN (5 mL). HATU (6.8 mg, 0.018 mmol) and DIEA 7 mg (0.054 mmol) were added. After 5 min, LCAA CPG (1000 Å, 0.5 g) was added. The reaction mixture was stirred at room temperature for 3 h. After filtration, the CPG was washed with MeCN (50 mL x 3), THF (50 mL x 3) and dried under vacuum. Capping A reagent: (THF / acetic anhydride / pyridine 80 / 10 / 10 v / v / v, 1.25 mL) and Capping B reagent: (1-methylimidazole / THF, 16 / 84, v / v, 1.25 mL) were added to the flask and the mixture was stirred at room temperature for 2 h. After filtration, the capped CPG was washed with EtOH (50 mL x 3), EtOH / pyridine (10%) (50 mL x 3), THF (50 mL x 3) and DCM (50 mL x 3). The capped CPG-bound compound 8 was then dried under vacuum. The loading was determined to be 49 μmol / g by standard DMTr assay by UV-Vis (498 nm). Example 2 Preparation of 2'-O-protected adenosine compound 13 and conjugation to solid support [ka]

[0137] Compound 9: N-benzoyl-adenosine (26 g, 70 mmol) was dissolved in pyridine (250 mL) and then 1,3-dichloro-1,1,3,3-tetraisopropyldisiloxane (25 g, 80 mmol) was added. The reaction was stirred at room temperature overnight and monitored by TLC. Most of the pyridine was removed, then the residue was redissolved in DCM and washed with brine. The organic layer was separated, dried over sodium sulfate, filtered and concentrated to dryness. The crude was used directly in the next step without further purification (50 g, HPLC purity: 72%, contains 28% pyridine). MS: Found: [M+H] = 614.4; Calculated: [M+H] = 614.3.

[0138] Compound 10: To a solution of compound 9 (50 g crude) in DMSO (50 mL) was added acetic anhydride (100 mL) and acetic acid (100 mL). The reaction mixture was heated to 50 degrees Celsius overnight and monitored by LCMS. Upon completion, the reaction was cooled to room temperature, concentrated, and quenched by pouring into saturated potassium carbonate (500 mL). The aqueous phase was extracted with DCM (500 mL), and then the organic phase was washed with brine (500 mL). The organic layer was dried with sodium sulfate, filtered, and concentrated. The residue was subjected to silica column purification using DCM / MeOH (0-4% MeOH) to give compound 10 (30 g, 64% for two steps) as a yellow solid. MS: Found: [M+H] = 674.6; Calculated: [M+H] = 674.3.

[0139] Compound 11: To a solution of compound 10 (2.2 g, 3.3 mmol) in DMF (15 mL) was added NBS (712 mg, 4.0 mmol). The reaction was stirred for 30 min, and then benzofuran-2-carboxylic acid (1.62 g, 10 mmol) was added. The reaction was monitored by TLC. Upon completion, the mixture was concentrated, diluted with DCM (20 mL), washed with water (3×20 mL), dried over sodium sulfate, evaporated, and subjected to silica column purification using DCM / MeOH (0-4% MeOH) to give compound 11 (565 mg, 22%) as a yellow oil. MS: Found: [M+H]=788.9; Calculated: [M+H]=788.31.

[0140] Compound 12: Compound 11 (0.565 g, 0.72 mmol) was dissolved in THF (10.2 mL) and TEA-3HF (0.15 mL, 0.90 mmol) was added. The reaction mixture was stirred at room temperature overnight. Upon completion, the reaction was diluted with saturated NaHCO 3 (5 mL) and the volatiles were removed in vacuo. DCM (10 mL) was added to extract the aqueous residue and the organic phase was separated. The aqueous phase was then extracted with DCM (3×10 mL). The combined organic phase was washed with Na 2 SO 4 The crude material was purified by flash column chromatography eluting with DCM and MeOH (0% to 12% MeOH) to give compound 12 as an off-white solid (0.20 g, 51.3% yield). MS: Found: [M+H] = 546.5; Calculated: [M+H] = 546.2.

[0141] Compound 13: Compound 12 (0.13 g, 0.24 mmol) was dissolved in pyridine (2.0 mL) and DMTrCl (0.12 g, 0.36 mmol) was added. The reaction mixture was stirred at room temperature overnight. After evaporation of the solvent, the crude material was purified by flash column chromatography eluted with DCM / MeOH (0-5% MeOH) to give compound 13 as pale yellow flakes (57 mg, 28.2% yield). MS: Found: [M+H] = 848.6; Calculated: [M+H] = 848.3.

[0142] Compound 14: To a solution of compound 13 (57 mg, 0.067 mmol) in DCM (1 ml) was added succinic anhydride (10.1 mg, 0.10 mmol) and triethylamine (13.6 mg, 0.136 mmol). The reaction was stirred overnight and monitored by LCMS. Upon completion, the mixture was concentrated and crude compound 14 was used directly without further purification. MS: Found: [MH] = 946.9; Calculated: [MH] = 946.29.

[0143] Compound 15: Crude compound 14 from above, 1000 Å LCAA CPG (0.7 g), TBTU (32.4 mg, 1.5 eq.), TEA (13.6 mg, 2 eq.) were dispersed in acetonitrile (3.5 mL). The mixture was placed in a rotovap and stirred at 25 degrees Celsius for 2 hours. The mixture was then filtered and the CPG was washed with acetonitrile (3×3 mL), THF (3×3 mL) and MTBE (3×3 mL) and dried under vacuum to give uncapped CPG. The uncapped CPG was then dispersed in THF (3.5 mL) containing acetic anhydride (0.14 mL), pyridine (0.14 mL) and NMI (0.14 mL). The reaction mixture was placed in a rotovap and stirred at 25 degrees Celsius for 1 hour. The capped CPG was then filtered, washed with 10% pyridine in ethanol (3×3 mL), ethanol (3×3 mL), MeCN (3×3 mL), THF (3×3 mL) and MTBE (3×3 mL) and dried to give solid support-bound compound 15. The loading was determined to be 26 μmol / g by standard DMTr assay by UV-Vis (498 nm). Example 3 Preparation of 2'-O-protected adenosine compound 18 and conjugation to solid support [ka]

[0144] Compound 16: To a solution of compound 10 (2.2 g, 3.3 mmol) in DMF (15 mL) was added NBS (712 mg, 4.0 mmol). The reaction mixture was stirred for 30 min, and then tetrahydro-2H-pyran-4-carboxylic acid (1.30 g, 10 mmol) was added. The reaction was monitored by TLC. Upon completion, the reaction mixture was concentrated, diluted with DCM (20 mL), washed with water (3×20 mL), dried over sodium sulfate, evaporated, and subjected to silica column purification using DCM / MeOH (0-4%) to give compound 16 (393 mg, 16% yield) as a yellow oil. MS: Found: [M+H]=756.7; Calculated: [M+H]=756.4.

[0145] Compound 17: Compound 16 (0.393 g, 0.52 mmol) was dissolved in THF (7.4 mL) and TEA-3HF (0.11 mL, 0.65 mmol) was added. The reaction mixture was stirred at room temperature overnight. Upon completion, the reaction was diluted with saturated NaHCO 3 (5 mL) and the volatiles were removed in vacuo. DCM (10 mL) was added to extract the aqueous residue and the organic phase was separated. The aqueous phase was then extracted with DCM (3×10 mL). The combined organic phase was washed with Na 2 SO 4 The crude material was purified by flash column chromatography eluting with DCM and MeOH (0% to 12% MeOH) to give compound 17 as an off-white solid (0.10 g, 37% yield). MS: Found: [M+H] = 514.6; Calculated: [M+H] = 514.2.

[0146] Compound 18: Compound 17 (80 mg, 0.16 mmol) was dissolved in pyridine (1.3 mL) and DMTrCl (58 mg, 0.17 mmol) was added. The reaction mixture was stirred at room temperature overnight. After evaporation of the solvent, the crude material was purified by flash column chromatography eluted with DCM / MeOH (0-5%) to give compound 18 as a pale yellow oil (30 mg, 23.6% yield). MS: Found: [M+H]=816.6; Calculated: [M+H]=816.3.

[0147] Compound 19: To a solution of compound 18 (30 mg, 0.037 mmol) in DCM (1 ml) was added succinic anhydride (5.5 mg, 0.055 mmol) and triethylamine (7.4 mg, 0.074 mmol). The reaction was stirred overnight and monitored by LCMS. Upon completion, the reaction mixture was concentrated and crude compound 19 was used directly without further purification. MS: Found: [MH] = 914.9; Calculated: [MH] = 914.3.

[0148] Compound 20: Crude compound 19 from above, 1000 Å LCAA CPG (0.3 g), TBTU (6.6 mg, 1.5 eq.), TEA (2.7 mg, 2 eq.) were dispersed in acetonitrile (1.5 mL). The mixture was placed in a rotovap and stirred at 25 degrees Celsius for 2 hours. The mixture was then filtered and the CPG was washed with acetonitrile (3×3 mL), THF (3×3 mL), and MTBE (3×3 mL), and dried to give uncapped CPG. The uncapped CPG was then dispersed in THF (1.5 mL) containing acetic anhydride (60 μL), pyridine (60 μL), and NMI (60 μL). The reaction mixture was placed in a rotovap and stirred at 25 degrees Celsius for 1 hour. The reaction mixture was then filtered and the capped CPG washed with 10% pyridine in ethanol (3×3 mL), ethanol (3×3 mL), MeCN (3×3 mL), THF (3×3 mL) and MTBE (3×3 mL) and dried to give solid support-bound compound 20. The loading was determined to be 14 μmol / g by standard DMTr assay by UV-Vis (498 nm). Example 4 2'-O-protected adenosine compound 23, preparation of phosphoramidite, and conjugation to solid support [ka]

[0149] Compound 21: To a solution of compound 10 (6.6 g, 10 mmol) in DMF (50 mL) was added NBS (2.2 g, 12 mmol). The reaction was stirred for 30 min before adding furan-2-carboxylic acid (3.50 g, 30 mmol). The reaction was monitored by TLC. Upon completion, the reaction mixture was concentrated, diluted with DCM (50 mL), washed with water (3×50 mL), dried with sodium sulfate and concentrated to dryness to give crude compound 21 (10 g), which was used directly without further purification. MS: Found: [M+H]=738.8; Calculated: [M+H]=738.3.

[0150] Compound 22: To a solution of crude compound 21 (10 g) in THF (100 mL) was added triethylamine trihydrogen fluoride (8.25 g, 50 mmol). The reaction was monitored by TLC. Upon completion, the mixture was quenched with sodium bicarbonate, concentrated, diluted with DCM (100 mL), washed with water (3×100 mL), dried with sodium sulfate, evaporated, and subjected to silica column using DCM / MeOH (0-8% MeOH) to give compound 22 (943 mg, 20% yield for two steps) as a pale yellow solid. MS: Found: [M+H]=496.4; Calculated: [M+H]=496.1.

[0151] Compound 23: To a solution of compound 22 (943 mg, 1.9 mmol) in pyridine (10 mL) was added DMTrCl (773 mg, 2.3 mmol). The reaction was monitored by TLC. Upon completion, the reaction mixture was quenched with methanol, concentrated, and subjected to silica column purification using DCM / MeOH (0-10% MeOH) to give compound 23 (535 mg, 35% yield) as a white solid. MS: Found: [M+H]=798.7; Calculated: [M+H]=798.3.

[0152] Compound 24: To a solution of compound 23 (120 mg, 0.15 mmol) in DCM (1.0 mL) was added succinic anhydride (22.5 mg, 0.225 mmol) and triethylamine (30 mg, 0.30 mmol). The reaction was stirred at room temperature overnight and monitored by LCMS. Upon completion, the reaction mixture was concentrated and crude compound 24 was used directly without further purification. MS: Found: [MH] = 896.9; Calculated: [MH] = 896.3.

[0153] Compound 25: Crude compound 24, 1000Å LCAA CPG (1.5 g), TBTU (72 mg, 1.5 eq.), TEA (30 mg, 2 eq.) were dispersed in acetonitrile (7.5 mL). The reaction mixture was placed in a rotovap and stirred at 25 degrees Celsius for 2 hours. The mixture was then filtered and the CPG was washed with acetonitrile (7.5 mL×3), THF (7.5 mL×3) and MTBE (7.5 mL×3) and dried under vacuum to give uncapped CPG. The uncapped CPG was then dispersed in THF (7.5 mL) containing acetic anhydride (0.3 mL), pyridine (0.3 mL) and NMI (0.3 mL). The reaction mixture was placed in a rotovap and stirred at 25 degrees Celsius for 1 hour. The reaction mixture was then filtered and the capped CPG was washed with 10% pyridine in ethanol (7.5×3 mL), ethanol (7.5×3 mL), MeCN (7.5×3 mL), THF (7.5×3 mL) and MTBE (7.5×3 mL) and dried under vacuum to give solid support-bound compound 25. The loading was determined to be 19 μmol / g by standard DMTr assay by UV-Vis (498 nm).

[0154] Compound 26: Compound 23 (400 mg, 0.5 mmol) and diisopropylammonium tetrazolide (21.4 mg, 0.125 mmol) were dissolved in DCM (4 mL) and then 3-((bis(diisopropylamino)phosphanyl)oxy)propanenitrile (301 mg, 1 mmol) was added. The reaction mixture was monitored by LCMS. Upon completion, the reaction was quenched with saturated sodium bicarbonate (3 mL) and washed with saturated sodium bicarbonate (3×3 mL) and brine (3 mL). The organic layer was dried with sodium sulfate, filtered and concentrated to dryness. The residue was redissolved in acetonitrile (3 mL) and washed with heptane (3×3 mL). The acetonitrile layer was concentrated and subjected to silica column purification using TEA / DCM (0.5% to 3% TEA) to give compound 26 (260 mg, 52% yield) as a white foam. MS: Found: [M+H] = 998.5; Calculated: [M+H] = 998.4. 31PNMR (mixture of diastereomers, DMSO-d 6 ):δ 150.573, 150.245. Example 5 2'-O-protected uridine compound 29 and conjugation to solid support [ka]

[0155] Compound 27: Compound 2 (2.4 g, 4.39 mmol) was dissolved in dichloromethane (60 mL) under a dry argon atmosphere and cooled to -10°C. Sulfuryl chloride (0.55 mL) was then added dropwise over 4 minutes. The reaction was stirred at room temperature for 1 hour. The solvent was then removed under reduced pressure to give a yellow foam which was subsequently dissolved in THF (40 mL). The sodium salt of 2-furoic acid (4.39 mmol) was then added to the stirred solution followed by 15-crown-5 (2.8 mmol). The reaction mixture was stirred for 1 hour and then diluted with H 2 The reaction mixture was quenched with O (50 mL). The solution was then transferred to a separatory funnel and the organic phase was separated. The aqueous layer was then washed with dichloromethane (3×50 mL). The combined organic layers were dried over magnesium sulfate. After filtration, the solvent was removed under reduced pressure to give a yellowish foam. The crude material was then purified by column chromatography (0-10% methanol in dichloromethane) to give compound 27 as a white foam solid (1.8 g, 37.3% yield). MS: Found: [MH]=609.5; Calculated: [MH]=609.2

[0156] Compound 28: Compound 27 (1.8 g, 2.9 mmol) was dissolved in THF (30 mL) and hydrogen fluoride pyridine (70% HF, 2.8 mL, 17.2 mmol) was added. The reaction was stirred at room temperature overnight. The reaction mixture was diluted with saturated NaHCO 3(20 mL) was added and then the solution was extracted with ethyl acetate (20 mL x 3). The organic phase was concentrated to dryness under vacuum. The crude material was then purified by column chromatography (0-10% MeOH in DCM) to give compound 28 as a white solid (146 mg, 13.6% yield). MS: Found [MH] = 367.4; Calculated: [MH] = 367.1.

[0157] Compound 29: Compound 28 (307 mg, 0.834 mmol) was dissolved in pyridine (25 mL) and then DMTrCl (310 mg, 0.917 mmol) was added. The reaction mixture was stirred at room temperature overnight. The reaction was quenched with 5% NaHCO3 solution and extracted with DCM (3 x 10 mL). The combined organic phase was dried over magnesium sulfate, filtered and concentrated to dryness. The crude material was then purified by column chromatography (0-10% MeOH in DCM) to give compound 29 as a white solid (330 mg, 58.7% yield). MS: Found [MH] = 699.5; Calculated: [MH] = 699.2.

[0158] Compound 30: Step 1: In a 50 mL RB flask, compound 29 (330 mg, 0.49 mmol) was dissolved in DCM (30 mL). Succinic anhydride (54 mg, 0.54 mmol), TEA (162 mg, 1.62 mmol) were added. The reaction mixture was stirred at room temperature for 2 h. The reaction was complete by TLC. The mixture was then diluted with saturated NaHCO 3 (10 mL) and DCM (20 mL) was added. The organic layer was separated and washed with water, brine and NaSO. 4 After filtration, the organic layer was concentrated to dryness under vacuum. The crude product was purified by column purification using DCM / MeOH (0%-10% MeOH). Pure fractions were collected and concentrated to dryness under vacuum to give the corresponding desired succinate (80 mg, 21% yield). MS: Found: [M+NH 4 ]=788.3; Calculated value: [M+NH 4 ]=788.2.

[0159] Step 2: In a 50 mL RB flask, the above succinate (222 mg (0.0288 mmol)) was dissolved in MeCN (5 mL). HATU (11 mg, 0.0288 mmol) and DIEA (11 mg, 0.0864 mmol) were added. After 5 min, LCAA CPG (1000 Å, 0.8 g) was added. The reaction mixture was stirred at room temperature for 3 h. After filtration, the CPG was washed with MeCN (50 mL×3) and THF (50 mL×3) and then dried under vacuum. Capping A reagent: (THF / acetic anhydride / pyridine 80 / 10 / 10 v / v / v, 2 mL) and Capping B reagent: (1-methylimidazole / THF, 16 / 84, v / v, 2 mL) were added to the flask and the mixture was stirred at room temperature for 2 h. After filtration, the capped CPG was washed with EtOH (50 mL x 3), EtOH / pyridine (10%) (50 mL x 3), THF (50 mL x 3) and DCM (50 mL x 3). The capped CPG was then dried under vacuum to give compound 30 bound to the solid support. The loading was determined to be 40 μmol / g by standard DMTr assay by UV-Vis (498 nm). Example 6 Deprotection of 2'-O-protected nucleosides [ka]

[0160] Compound 5 (10 mg, 0.0233 mmol) was dissolved in THF (0.5 mL) and diluted with 2.0 M NH 3 (0.4 mL, 0.89 mmol) was added. The reaction mixture was stirred at room temperature overnight and TLC showed the reaction was complete. The volatiles were removed in vacuo to give uridine. MS: Found: [MH] = 243.3; Calculated: [MH] = 243.1. [ka]

[0161] Compound 12 (70 mg, 0.13 mmol) was dissolved in THF (2.6 mL) and diluted with 2.0 M NH 3 (2.4 mL) was added. The reaction mixture was stirred at room temperature overnight and monitored by TLC. Upon completion, the volatiles were removed under vacuum and the residue was dissolved in MeOH (0.5 mL) and MTBE was added to precipitate. The solid was then filtered and dried under vacuum to give N6-benzoyladensoine (25.6 mg, 53.9% yield). MS: Found: [M+H] = 372.1; Calculated: [M+H] = 372.1. [ka]

[0162] Compound 17 (20 mg, 0.039 mmol) was dissolved in THF (0.78 mL) and diluted with 2.0 M NH 3 (0.74 mL) was added. The reaction mixture was stirred at room temperature overnight and monitored by TLC. Upon completion, the volatiles were removed under vacuum and the residue was dissolved in MeOH (0.2 mL) and MTBE was added to precipitate. The solid was then filtered and dried under vacuum to give N6-benzoyl adenosine (5.4 mg, 37.5% yield). MS: Found: [M+H] = 372.1; Calculated: [M+H] = 372.1. [ka]

[0163] Compound 28 (3 mg, 0.008 mmol) was dissolved in THF (0.2 mL) and diluted with 2.0 M NH 3 (0.15 mL) was added. The reaction mixture was stirred at room temperature overnight and TLC showed the reaction was complete. The volatiles were removed in vacuo to give uridine. MS: Found: [MH] = 243.3; Calculated: [MH] = 243.1.

[0164] Example 7 Preparation of oligonucleotides Oligonucleotides were synthesized on a DNA / RNA synthesizer starting from the DMTr-nucleoside-phosphoramidites described herein. A standard synthesis cycle useful in assembling oligonucleotides includes the steps of (a) detritylation of the solid phase-bound material, (b) coupling of the nucleoside phosphoramidite building blocks required by the sequence to the solid support-bound material in the presence of a coupling agent, (c) capping of unreacted hydroxy groups bound to the solid support with a mixture of acetic anhydride and N-methylimidazole, and (d) oxidation of the phosphite triester groups bound to the solid support. The appropriate cycle to assemble the desired oligonucleotide was repeated as required by the sequence as prepared.

[0165] Final release of the oligonucleotides from the solid support, deprotection of the internucleoside phosphate and monosaccharide residues was achieved by treatment under standard conditions as follows: Upon completion of deprotection under the above conditions, the liquid phase was collected and evaporated to dryness in vacuo. The residue was dissolved in water (1 mL) and analyzed by reversed-phase HPLC and ES MS.

[0166] To demonstrate the utility of these 2'-O-protected RNA solid supports in DNA / RNA oligonucleotide synthesis, the following sequence was designed for testing: 5'-TTTTTTTTTT (SEQ ID NO: 1)-Y-3' (Y represents the solid support conjugated with a 2'-O-protected RNA nucleoside), thereby generating the following compounds: T10Y1, T10Y2, T10Y3, T10Y4 and T10Y5.

[0167] Oligonucleotides (compounds T10Y1 to T10Y5) were synthesized by the solid-phase phosphoramidite method. The solid support (Y) conjugated with 2'-O-protected RNA was packed into an empty column and placed in a MerMade 6 synthesizer. The synthesis scale was 0.5-1 μmol. The cycle for oligonucleotide synthesis included the following steps: (1) detritylation with 3% trichloroacetic acid in dichloromethane for 45 seconds twice, followed by an acetonitrile wash; (2) coupling with 0.1 M DMT-dT-CE-phosphoramidite (5'-O-(4,4'-dimethoxytrityl)-thymidine-3'-cyanoethyl phosphoramidite) in acetonitrile and 0.5 M activator (tetrazole in acetonitrile) for 1 minute twice, followed by an acetonitrile wash; (3) oxidation with iodine (0.015 M iodine in water / pyridine / THF 2 / 20 / 78) for 45 seconds, followed by an acetonitrile wash; and (4) capping with a mixture of acetic anhydride, pyridine and THF for 45 seconds, followed by an acetonitrile wash. To synthesize 2'-O-protected RNA-conjugated solid support-extended T10, steps (1)-(4) were repeated 10 times, completed by a final detritylation with acetonitrile washes.

[0168] After synthesis, the oligonucleotide-bound solid support was treated with a 1:1 mixture of aqueous ammonium hydroxide and methylamine at 55°C for 2 hours for cleavage and deprotection. The 2'-O-protecting group is also removed in this step. Upon completion, the liquid phase was collected and thermally dried in vacuum. The dried residue was dissolved in water and analyzed by reverse-phase HPLC (Agilent 1260) and LC-MS (Applied Biosystems 4000Q-Trap). The HPLC gradient was 20% to 60% B in 20 min, with A: 50 mM triethylammonium acetate in water, and B: 80% 50 mM triethylammonium acetate in water and 20% acetonitrile. The retention times (RT), calculated MS, observed MS and full-length product purity (FLP) for each sequence (compounds T10Y1, T10Y2, T10Y3, T10Y4 and T10Y5) are listed in Table 1. Table 1. Testing the use of 2'-O-protected RNA-conjugated solid supports [Table 1]

[0169] Although the present application has been described with reference to specific embodiments thereof, it should be understood by those skilled in the art that various changes may be made and equivalents may be substituted without departing from the true spirit and scope of the present application. In addition, many modifications may be made to adapt a particular situation, material, composition of matter, process, process step or steps to the objective, spirit and scope of the present application. All such modifications are intended to be within the scope of the claims appended hereto.

Claims

1. Formula (I): 【Chemistry 88】 or a pharma- ceutically acceptable salt thereof, wherein R 1 is hydrogen or a hydroxy protecting group, R 2 is hydrogen, a hydroxy protecting group, -C(=O)CH 2 CH 2 C(=O)R 3 Or -P(OR 4 ) N.R. 5 R 6 and Alternatively, R 1 and R 2 are joined together to form a 6- to 10-membered heterocyclic ring; R Het is an optionally substituted 5-10 membered heteroaryl or an optionally substituted 5-10 membered heterocyclyl; R 3 is hydroxy, -OR 7 Or -NR 8 R 9 and R 4 , R 5 and R 6 Each independently represents H, unsubstituted C 1 ~C 6 Alkyl or substituted C 1 ~C 6 is alkyl, R 7 is unsubstituted C 1 ~C 6 Alkyl, substituted C 1 ~C 6 is an alkyl or hydroxy protecting group, R 8 and R 9 Each independently represents H, unsubstituted or substituted C 1~6 an alkyl or amino protecting group, B is a natural nucleobase, a modified natural nucleobase or a non-natural nucleobase; The compound or a pharma- ceutically acceptable salt thereof.

2. R 1 is a trityl-type hydroxy protecting group selected from the group consisting of (4-methoxyphenyl)diphenylmethyl, bis(4-methoxyphenyl)phenylmethyl, tris(4-methoxyphenyl)methyl, 9-phenylxanthen-9-yl and 9-(4-methoxyphenyl)xanthen-9-yl.

3. R 1 The compound according to claim 1 or 2, wherein is bis(4-methoxyphenyl)phenylmethyl.

4. R 1 The compound of claim 1 , wherein is hydrogen.

5. R 2 The compound according to any one of claims 1 to 4, wherein is H.

6. R 2 But -P(OR 4 ) N.R. 5 R 6 where R 4 But substitution C 1 ~C 6 is alkyl, R 5 and R 6 each independently represents an unsubstituted C 1 ~C 6 is alkyl, A compound according to any one of claims 1 to 4.

7. R 2 but, 【Chemistry 89】 7. The compound of claim 6,

8. R 1 and R 2 The compound of claim 1 , wherein:

9. The compound of formula (I) may also be represented by the formula (Ia): 【Chemistry 90】 or a pharma- ceutically acceptable salt thereof, A , R B , R C and R D are each independently H, unsubstituted C 1 ~C 6 Alkyl or substituted C 1 ~C 6 is alkyl, The compound according to claim 8.

10. R A , R B , R C and R D The compound of claim 9 , wherein each is isopropyl.

11. R Het is an optionally substituted 5-10 membered heteroaryl containing 1-4 heteroatoms selected from the group consisting of O, N and S.

12. R Het is selected from the group consisting of pyridinyl, pyrimidinyl, furanyl, pyrrolyl, thienyl, thiazolyl, isothiazolyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, benzofuranyl, benzimidazolyl, benzopyrazolyl, benzothiazolyl, benzoxazolyl, indolyl and quinolinyl, each of which is optionally substituted by one, two or three substituents Q, each of which is halo, cyano, hydroxy, amino, C 1 ~C 6 Alkyl, C 1 ~C 6 Haloalkyl, Hydroxy (C 1 ~C 6 Alkyl), amino (C 1 ~C 6 Alkyl), (C 1 ~C 6 Alkyl)amino, C 1 ~C 6 Alkoxy, C 1 ~C 6 Haloalkoxy, (C 1 ~C 6 Alkoxy)C 1 ~C 6 Alkyl and -O(C 1 ~C 6 Alkoxy)C 1 ~C 6 12. The compound of claim 11, wherein said compound is independently selected from the group consisting of alkyl.

13. R Het is an optionally substituted 5-10 membered heterocyclyl containing 1 to 4 heteroatoms selected from the group consisting of O, N and S.

14. R Het is selected from the group consisting of tetrahydrofuranyl, tetrahydropyranyl, pyrrolidinyl, piperidinyl, piperazinyl and morpholinyl, each of which is optionally substituted with one, two or three substituents Q, each of which is halo, cyano, hydroxy, amino, C 1 ~C 6 Alkyl, C 1 ~C 6 Haloalkyl, Hydroxy (C 1 ~C 6 Alkyl), amino (C 1 ~C 6 Alkyl), (C 1 ~C 6 Alkyl)amino, C 1 ~C 6 Alkoxy, C 1 ~C 6 Haloalkoxy, (C 1 ~C 6 Alkoxy)C 1 ~C 6 Alkyl and -O(C 1 ~C 6 Alkoxy)C 1 ~C 6 14. The compound of claim 13, wherein each of the groups is independently selected from the group consisting of alkyl.

15. Q is -F, -Cl, -Br, -CH 3 , -CH 2 CH 3 , -CF 3 , -CH 3 , -OCH 3 and -OCH 2 CH 3 15. The compound of claim 12 or 14, independently selected from the group consisting of:

16. B, 【Chemistry 91】 where R x is hydrogen, unsubstituted or substituted C 1 ~C 6 an alkyl or amino protecting group, or -NHR x There is no hydrogen in R x The compound according to any one of claims 1 to 15, wherein is a divalent amino protecting group.

17. R x is -C(=O)Ph(Bz), -C(=O)CH 3 (Ac) or -C(=O)CH(CH 3 ) 2 (iBu) or -NHR x There is no hydrogen in R x but, 【Chemistry 92】 17. The compound of claim 16,

18. below: 【Chemistry 93】 【Chemistry 94】 2. The compound according to claim 1 , wherein R 2 H, 【Chemistry 95】 -C(=O)CH 2 CH 2 C(=O)OH or -C(=O)CH 2 CH 2 C(=O)NH 2 and 【Chemistry 96】 is optionally substituted with 1 to 3 substituents Q, where Q is each -F, -Cl, -Br, -CH 3 , -CH 2 CH 3 , -CF 3 , -CH 3 , -OCH 3 and -OCH 2 CH 3 Independently selected from the group consisting of: compound.

19. B, 【Chemistry 97】 where R x is -C(=O)Ph(Bz), -C(=O)CH 3 (Ac) or -C(=O)CH(CH 3 ) 2 20. The compound of claim 18, wherein said compound is (iBu).

20. 20. A method for preparing a synthetic oligonucleotide comprising reacting a compound according to any one of claims 1 to 19 with an oligonucleotide.

21. 21. The method of claim 20, wherein the oligonucleotide has a length of 1 to 100 nucleobases.

22. 22. The method of claim 20 or 21, wherein the reaction is carried out on a solid support.

23. Formula (II): 【Chemistry 98】 1. A method for deprotecting an oligonucleotide or polynucleotide comprising at least one 2′ protected nucleotide residue comprising the structure: X is O or S; R 4 is H, unsubstituted C 1 ~C 6 Alkyl or substituted C 1 ~C 6 is alkyl, B is a natural nucleobase, a modified natural nucleobase or a non-natural nucleobase; R Het is an optionally substituted 5-10 membered heteroaryl or an optionally substituted 5-10 membered heterocyclyl; The method comprises: The method comprises the step of contacting said oligonucleotide or polynucleotide with a composition comprising an amine or ammonia to deprotect said 2' protected nucleotide residue.

24. B, 【Chemistry 99】 Wherein R x is hydrogen, unsubstituted or substituted C 1 ~C 6 an alkyl or amino protecting group, or -NHR x There is no hydrogen in R x is a divalent amino protecting group; 24. The method of claim 23.

25. R 4 is H, -CH 2 CH 2 25. The method of claim 23 or 24, wherein said alkyl group is CN or methyl.

26. 26. The method of any one of claims 23 to 25, wherein X is O.

27. R Het is an optionally substituted 5-10 membered heteroaryl containing 1 to 4 heteroatoms selected from the group consisting of O, N and S.

28. R Het is selected from the group consisting of pyridinyl, pyrimidinyl, furanyl, pyrrolyl, thienyl, thiazolyl, isothiazolyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, benzofuranyl, benzimidazolyl, benzopyrazolyl, benzothiazolyl, benzoxazolyl, indolyl and quinolinyl, each optionally substituted by one, two or three substituents Q, each of which is halo, cyano, hydroxy, amino, C 1 ~C 6 Alkyl, C 1 ~C 6 Haloalkyl, Hydroxy (C 1 ~C 6 Alkyl), amino (C 1 ~C 6 Alkyl), (C 1 ~C 6 Alkyl)amino, C 1 ~C 6 Alkoxy, C 1 ~C 6 Haloalkoxy, (C 1 ~C 6 Alkoxy)C 1 ~C 6 Alkyl and -O(C 1 ~C 6 Alkoxy)C 1 ~C 6 28. The method of claim 27, wherein each of the groups is independently selected from the group consisting of alkyl.

29. R Het is an optionally substituted 5-10 membered heterocyclyl containing 1 to 4 heteroatoms selected from the group consisting of O, N and S.

30. R Het is selected from the group consisting of tetrahydrofuranyl, tetrahydropyranyl, pyrrolidinyl, piperidinyl, piperazinyl and morpholinyl, each of which is optionally substituted with one, two or three substituents Q, each of which is halo, cyano, hydroxy, amino, C 1 ~C 6 Alkyl, C 1 ~C 6 Haloalkyl, Hydroxy (C 1 ~C 6 Alkyl), amino (C 1 ~C 6 Alkyl), (C 1 ~C 6 Alkyl)amino, C 1 ~C 6 Alkoxy, C 1 ~C 6 Haloalkoxy, (C 1 ~C 6 Alkoxy)C 1 ~C 6 Alkyl and -O(C 1 ~C 6 Alkoxy)C 1 ~C 6 30. The method of claim 29, wherein said alkyl is independently selected from the group consisting of alkyl.

31. the 2' nucleotide residue is 【Chemistry 100】 wherein: R 4 is H or -CH 2 CH 2 CN, B is, 【Chemistry 101】 and R x is -C(=O)Ph(Bz), -C(=O)CH 3 (Ac) or -C(=O)CH(CH 3 ) 2 (iBu), 【Chemistry 102】 each is optionally substituted with 1 to 3 substituents Q; Q is -F, -Cl, -Br, -CH 3 , -CH 2 CH 3 , -CF 3 , -CH 3 , -OCH 3 and -OCH 2 CH 3 Independently selected from the group consisting of:

27. The method of any one of claims 23 to 26.

32. 32. The method of any one of claims 23 to 31, wherein the composition comprises a solvent.

33. 33. The method of claim 32, wherein the solvent comprises methanol.

34. 34. The method of any one of claims 23 to 33, wherein the oligonucleotide or polynucleotide is attached to a solid support.

35. 35. An oligonucleotide or polynucleotide prepared by the method of any one of claims 20 to 34.

36. Formula (II): 【Chemistry 103】 1. A solid support-bound oligonucleotide or polynucleotide comprising at least one 2′-protected nucleotide residue comprising the structure: X is O or S; R 4 is H, unsubstituted C 1 ~C 6 Alkyl or substituted C 1 ~C 6 is alkyl, B is a natural nucleobase, a modified natural nucleobase or a non-natural nucleobase; R Het is an optionally substituted 5-10 membered heteroaryl or an optionally substituted 5-10 membered heterocyclyl; An oligonucleotide or polynucleotide bound to a solid support.

37. B, 【Chemistry 104】 【Chemistry 105】 and R x is hydrogen, unsubstituted or substituted C 1 ~C 6 an alkyl or amino protecting group, or -NHR x There is no hydrogen in R x is a divalent amino protecting group; 37. An oligonucleotide or polynucleotide bound to a solid support according to claim 36.

38. R 4 is H, -CH 2 CH 2 38. A solid support-bound oligonucleotide or polynucleotide according to claim 36 or 37, wherein said oligonucleotide or polynucleotide is CN or methyl.

39. 39. The solid support bound oligonucleotide or polynucleotide of any one of claims 36 to 38, wherein X is O.

40. R Het is an optionally substituted 5-10 membered heteroaryl containing 1-4 heteroatoms selected from the group consisting of O, N and S.

41. R Het is selected from the group consisting of pyridinyl, pyrimidinyl, furanyl, pyrrolyl, thienyl, thiazolyl, isothiazolyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, benzofuranyl, benzimidazolyl, benzopyrazolyl, benzothiazolyl, benzoxazolyl, indolyl and quinolinyl, each optionally substituted by one, two or three substituents Q, each of which is halo, cyano, hydroxy, amino, C 1 ~C 6 Alkyl, C 1 ~C 6 Haloalkyl, Hydroxy (C 1 ~C 6 Alkyl), amino (C 1 ~C 6 Alkyl), (C 1 ~C 6 Alkyl)amino, C 1 ~C 6 Alkoxy, C 1 ~C 6 Haloalkoxy, (C 1 ~C 6 Alkoxy)C 1 ~C 6 Alkyl and -O(C 1 ~C 6 Alkoxy)C 1 ~C 6 41. The solid support of claim 40, wherein each of said groups is independently selected from the group consisting of alkyl.

42. R Het is an optionally substituted 5-10 membered heterocyclyl containing 1-4 heteroatoms selected from the group consisting of O, N and S.

43. R Het is selected from the group consisting of tetrahydrofuranyl, tetrahydropyranyl, pyrrolidinyl, piperidinyl, piperazinyl and morpholinyl, each of which is optionally substituted with one, two or three substituents Q, each of which is halo, cyano, hydroxy, amino, C 1 ~C 6 Alkyl, C 1 ~C 6 Haloalkyl, Hydroxy (C 1 ~C 6 Alkyl), amino (C 1 ~C 6 Alkyl), (C 1 ~C 6 Alkyl)amino, C 1 ~C 6 Alkoxy, C 1 ~C 6 Haloalkoxy, (C 1 ~C 6 Alkoxy)C 1 ~C 6 Alkyl and -O(C 1 ~C 6 Alkoxy)C 1 ~C 6 43. The solid support bound oligonucleotide or polynucleotide of claim 42, wherein each of said oligonucleotides or polynucleotides is independently selected from the group consisting of alkyl.

44. The 2' nucleotide residue 【Chemistry 106】 is selected from the group consisting of B, 【Chemistry 107】 and R x is -C(=O)Ph(Bz), -C(=O)CH 3 (Ac) or -C(=O)CH(CH 3 ) 2 (iBu), 【Chemistry 108】 are each optionally substituted with 1 to 3 substituents Q; Q is -F, -Cl, -Br, -CH 3 , -CH 2 CH 3 , -CF 3 , -CH 3 , -OCH 3 and -OCH 2 CH 3 Independently selected from the group consisting of:

40. An oligonucleotide or polynucleotide bound to a solid support according to any one of claims 36 to 39.